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Personality pathology, especially antisocial personality disorder (ASPD), often occurs in 
patients with methamphetamine use disorder (MAUD).  However, little is known about 
potential risk factors for this dual diagnosis, and the impact of this comorbidity on both the 
severity of MAUD and levels of functional impairment.  Casting light on such phenomena 
may aid in early identification of treatment targets, assist in the management of patients in 
this particular population, and contribute to development of treatment strategies.  This cross-
sectional study described and compared sociodemographic, clinical and childhood trauma 
correlates in patients with a dual diagnosis of MAUD and ASPD (MAUD+ASPD) and those 
with MAUD without ASPD (MAUD-ASPD).  The contribution of sociodemographic and 
childhood trauma variables in predicting membership of the MAUD+ASPD group was also 
investigated. 
A sample of 62 adult patients with a primary diagnosis of MAUD took part in the 
study.  A sociodemographic questionnaire was completed and well established diagnostic 
measures of ASPD (The Mini-International Neuropsychiatric Interview; MINI) and MAUD 
(Structured Clinical Interview; SCID - 5) were used to determine diagnostic status.  Illness 
severity was evaluated with the Yale-Brown Obsessive Compulsive scale (adapted for 
MAUD) (Y-BOCS-du) and functional impairment was assessed with the Sheehan Disability 
Scale (SDS).   Histories of exposure and severity of childhood trauma (CT) were measured 
using the CTQ-SF.   
Of the 62 participants, 14 (23%) had MAUD and had MAUD+ASPD whereas 48 
(77%) had MAUD without ASPD (MAUD-ASPD).  Bivariate analyses found significant 
group differences in terms of gender (df =1) = 8.05; p = <0.01), language (df = 2) = 7.12; p = 
0.03), and level of physical neglect (F(1, 60) = 2.33; M = 9.85; SD = 4.23; p = 0.04).  The 
MAUD+ASPD group members were mostly male (N = 9; 64%), English-speaking and with 
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histories of increased physical neglect.  Logistic regression suggested that male gender (beta 
= 1.08; OR = 8.65; p = 0.01) and English language (beta = 1.55; OR = 11.38; p = 0.03) 
significantly predicted ASPD comorbidity.  There were no significant differences in clinical 
severity or functional impairment between the MAUD+ASPD and MAUD-ASPD groups. 
In conclusion, this study indicated that male gender and having English as a first 
language are associated with MAUD+ASPD but other sociodemographic variables, CT 
histories and clinical severity and impairment were not.  Men who use MA are thus more 
prone to antisocial behaviour, which complicates their substance use condition.  Treatment 
approaches for MAUD may benefit from developing adaptations that cater for challenges 
specific to comorbid ASPD.   Additionally, the finding regarding first language warrants 
further investigation. Recommendations for future research are suggested.  
 
Keywords:  Antisocial personality disorder; methamphetamine use disorder; childhood 

















 TABLE OF CONTENTS 
DECLARATION ....................................................................................................................... 2 
DEDICATION ........................................................................................................................... 3 
ACKNOWLEDGEMENTS ....................................................................................................... 4 
ABSTRACT ............................................................................................................................... 6 
TABLE OF CONTENTS ........................................................................................................... 8 
LIST OF TABLES ................................................................................................................... 11 
LIST OF ABBREVIATIONS .................................................................................................. 12 
CHAPTER ONE ...................................................................................................................... 13 
INTRODUCTION ................................................................................................................... 13 
1.1  Research Aims and Objectives ................................................................................... 16 
1.2  Structure of Dissertation ............................................................................................ 17 
CHAPTER TWO ..................................................................................................................... 18 
LITERATURE REVIEW ........................................................................................................ 18 
2.1  Methamphetamine Use Disorder (MAUD) ................................................................... 18 
2.1.1  Methamphetamine ................................................................................................... 18 
2.1.2  Methamphetamine Use Disorder ............................................................................. 18 
2.1.3  Impact of Methamphetamine Use ........................................................................... 20 
2.1.4  Illness Severity and Psychosocial Disability ........................................................... 23 
2.2  Antisocial Personality Disorder (ASPD) ....................................................................... 24 
2.2.1. Comorbidity of Methamphetamine Use Disorder and Antisocial Personality 
Disorder ............................................................................................................................. 25 
2.3  Childhood Trauma (CT) ................................................................................................ 27 
9 
 
2.4  Childhood Trauma, Methamphetamine Use Disorder and Antisocial Personality 
Disorder ................................................................................................................................ 27 
2.4.1  Childhood Trauma and Methamphetamine Use Disorder....................................... 28 
2.4.2  Childhood Trauma and Antisocial Personality Disorder ........................................ 30 
2.5  Conclusion .................................................................................................................. 30 
CHAPTER THREE ................................................................................................................. 32 
METHODOLOGY .................................................................................................................. 32 
3.1  Research Design ......................................................................................................... 32 
3.2  Research Questions .................................................................................................... 33 
3.3  Sample ........................................................................................................................ 34 
3.4  Instruments ................................................................................................................. 34 
3.5  Procedures .................................................................................................................. 39 
3.6  Data Analysis ............................................................................................................. 40 
3.7  Ethics .......................................................................................................................... 41 
3.8  Informed Consent ....................................................................................................... 41 
3.9  Anonymity and Confidentiality .................................................................................. 42 
3.10  Risks and Benefits .................................................................................................... 42 
3.11  Incentives ................................................................................................................. 42 
CHAPTER  FOUR ................................................................................................................... 43 
RESULTS ................................................................................................................................ 43 
4.1  Demographic Characteristics ..................................................................................... 43 
4.2  Associations Between Diagnostic Group and Demographic Variables ..................... 44 
4.3  Association between Diagnostic Group and Illness Severity .................................... 45 
4.4  Association between Diagnostic Group and Psychosocial Functioning .................... 46 
4.5  Childhood Trauma ..................................................................................................... 47 
10 
 
4.6  Predicting Group Membership ................................................................................... 49 
4.7  Conclusion .................................................................................................................. 50 
CHAPTER FIVE ..................................................................................................................... 51 
DISCUSSION .......................................................................................................................... 51 
5.1. Rates of Methamphetamine Use Disorder with comorbid Antisocial Personality 
Disorder ............................................................................................................................. 51 
5.2  Demographic Features of the Sample ........................................................................ 52 
5.3  Demographic Factors Associated with Comorbid Antisocial Personality Disorder .. 54 
5.4  Association of Childhood Trauma with Methamphetamine Use Disorder ................ 56 
5.4.1  Childhood Trauma and Group Membership ........................................................ 58 
5.5  Illness Severity and Psychosocial Disability .............................................................. 59 
5.6  Predicting Comorbid Antisocial Personality Disorder in Methamphetamine Use 
Disorder ............................................................................................................................. 60 
5.7  Limitations and Recommendations ............................................................................ 62 
5.8  Conclusion .................................................................................................................. 63 
Acknowledgements .............................................................................................................. 65 
References ............................................................................................................................ 66 
Appendix A - Demographics Questionnaire ........................................................................ 84 
Appendix B - SCID-RV (for DSM-5®) Module E for Substance Use Disorders ................ 86 
Appendix C - MINI – Antisocial Personality Disorder ........................................................ 95 
Appendix D - Childhood Trauma Questionnaire ................................................................. 97 
Appendix E – Yale Brow Obsessive Compulsive Scale (adapted for drug use) .................. 99 
Appendix F - Sheehan Disability Scale (SDS) ................................................................... 104 






LIST OF TABLES 
Table 1: Demographic features of the total sample………………………………………… 42 
Table 2: Comparison of the demographic features of the two diagnostic groups.….…....… 44 
Table 3: Comparison of illness severity of the two diagnostic groups………….………….. 45 
Table 4: Comparison of psychosocial functioning of the two diagnostic groups…………... 45 
Table 5: Comparison of rates and severity of exposure to CT between the two diagnostic 
groups……………………………………………………………………………………….. 47 
Table 6:  Test of all effects for predicting group membership………………………...…… 49 

















LIST OF ABBREVIATIONS 
APA – American Psychological Association 
ASPD – Antisocial Personality Disorder 
CT – Childhood Trauma 
CTQ-SF – Childhood Trauma Questionnaire (Short Form) 
DSM 5 – The Diagnostic and Statistical Manual of Mental Disorders (fifth edition) 
MA – Methamphetamine  
MINI - The Mini-International Neuropsychiatric Interview (MINI) 
MAUD – Methamphetamine Use Disorder 
MAUD+ASPD – Methamphetamine Use Disorder with comorbid Antisocial Personality 
Disorder 
MAUD-ASPD – Methamphetamine Use Disorder without Antisocial Personality Disorder 
SCID – 5.  The Substance Use Disorder module of the Structured Clinical Interview for 
DSM-5 Disorders (SCID-5)  
SDS – Sheehan Disability Scale 
SUD – Substance Use Disorder 













In recent years, methamphetamine (MA) use has become a significant problem in South 
Africa (Dada et al., 2016; Plüddemann et al., 2013).  In the Western Cape Province, MA use 
has reportedly reached epidemic proportions (Dada et al., 2017).   
Methamphetamine use disorder (MAUD) is a psychiatric condition characterized by a 
pattern of MA use that results in significant distress or impairment on multiple levels of 
functioning (American Psychiatric Association (APA), 2013).  Individuals with MAUD 
present with several symptoms which include tolerance, withdrawal when MA use is stopped 
or reduced, and craving for the substance (APA, 2013).  In general and locally, MA use and 
MAUD have burdened public health and social services greatly, with demands ranging from 
a physical, psychological and psychiatric sequela, as well as social and intrapersonal in nature 
(Akindipe, Wilson, & Stein, 2014; Aronson, 2016; Kalechstein et al., 2000; Polcin, Buscemi, 
Nayak, Korcha, & Galloway, 2012; Richards & Laurin, 2017; Salo et al., 2011; Watt et al., 
2014; Yen & Chong, 2006).  Problems associated with MA use and MAUD are complicated, 
with varied treatment success (Polcin et al., 2012).  Often treatment non-compliance, relapse 
rates, illness severity, and functional impairment are high (Cohen et al., 2007; Eslami-
Shahrbabaki et al., 2015; Gonzales et al., 2011; Grant et al., 2010).   
Comorbidity of personality pathology appears to be common in substance use 
disorder (SUD) patients (Verheul, 2001), with antisocial personality disorder (ASPD) being 
especially prevalent (Le Bon et al., 2004).  There is also some evidence that personality 
pathology, and specifically ASPD, are highly prevalent in patients with MAUD (Zhang et al., 
2018).  Antisocial personality disorder is a psychiatric diagnosis classified among the 
personality disorders in the Diagnostic and Statistical Manual of Mental Disorders – fifth 
edition (DSM-5) and is characterized by a continuous disregard for, as well as violation of, 
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the rights and safety of others that often has its onset in childhood or adolescence (APA, 
2013).  It is often hallmarked with actions that are deceitful and presents with a pattern of 
lying, using aliases, or conning others for self-profit or pleasure (APA, 2013).  Individuals 
with ASPD may also demonstrate a lack of remorse, as indicated by being indifferent to the 
realization of hurting, mistreating or stealing from others.  Some of these characteristics and 
behaviours (e.g. being deceitful or untrustworthy, increased impulsivity, lack of obligation, 
lying and cheating, poor connection with others and  aggression and violence) are similar to 
those that are often found in people with substance use disorder (Sommers, Baskin, & 
Baskin-Sommers, 2006; Watt et al., 2014; Watt, Guidera, Hobkirk, Skinner, & Meade, 2016).  
To date most dual diagnosis research with MAUD patients has focused on mood and 
anxiety disorders, rather than personality pathology.  In a few studies with both SUD and 
MAUD patients, ASPD has been associated with poorer prognosis and increased risk for 
treatment drop-out and relapse (Messina, Farabee, & Rawson, 2003; Zhang et al., 2018).  The 
comorbidity of personality pathology has also been associated with increased severity of 
substance use (Zhang et al., 2018).  However, the difference in clinical severity and 
functional impairment (and, hence, treatment needs and prognosis) between MAUD patients 
with and without ASPD comorbidity is not yet well understood.  
Furthermore, it appears that there is limited research on risk factors for ASPD 
comorbidity in individuals with a primary diagnosis of MAUD.  Sociodemographic factors 
may increase the risk for this dual diagnosis, but other than the well-established finding that 
both MAUD and ASPD are more common in men (Holzer & Vaughn, 2017), research on 
sociodemographic risk factors for MAUD+ASPD are limited.  
Some circumstances may render people more vulnerable for developing 
psychopathology.  Adversity during childhood is a global phenomenon that affects the lives 
of people worldwide (Stoltenborgh et al., 2015).  Childhood adversity is often referred to as 
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childhood trauma (CT), which can broadly be defined as the exposure to traumatic events in 
childhood that may result in adverse developmental consequences (Busuttil, 2009; 
Gregorowski & Seedat, 2013).  Also common in the South African context (Hobkirk et al., 
2015; Kaminer et al., 2013; Williams et al., 2007), such histories place individuals at higher 
risk for acute and chronic physical, emotional or psychiatric problems compared to those with 
relatively trauma-free childhoods (Stoltenborgh et al., 2011).   
Childhood trauma and adversity have been linked to several psychiatric conditions, 
including SUDs (Lieberman et al., 2011) as well as personality pathology (APA, 2013; 
Kounou et al., 2013).  It appears that people with adverse childhood experiences have a 
significantly higher risk of both MAUD (Ding et al., 2014) and ASPD (Semiz et al., 2007).  
More specifically, some research has implicated CT in the development and onset of both 
MAUD and ASPD (Brown et al., 2003; Cohen et al., 2007; Kounou et al., 2013; Lopez-
Patton et al., 2016; Messina et al., 2008; Semiz et al., 2007; Sher et al., 2015).   
While there is some evidence that people with MAUD with histories of CT are at risk 
for comorbid ASPD (Lecomte et al., 2010), the role of CT in the risk for a dual diagnosis of 
MAUD and ASPD (MAUD+ASPD) remains unclear.  It further appears that the role of CT in 
MAUD+ASPD has not been well explored in lower income countries like South Africa 
where rates of CT are high compared to higher income settings.  This study was conducted in 
response to recent local pleas for more research on MA use as a matter of social 
development, safety, and public health (Mushanyu et al., 2015; Watt et al., 2014; Wyk & 
Stuart, 2011).  Current and ongoing research on MAUD, specifically, conducted by the 
Medical Research Council’s Unit on Risk and Resilience in Mental Disorders offered a 
cohort of South African adult patients with a primary diagnosis of MAUD and presented the 
opportunity to investigate the prevalence and correlates of comorbid ASPD.  In the South 
African context, there is an exceptionally high prevalence of MA use, but research on 
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personality pathology in MAUD seems to be limited.  A dual diagnosis of MAUD+ASPD 
may negatively impact illness severity and psychosocial functioning, which in turn, may 
create barriers to successful treatment, such as treatment dropout..  Understanding more about 
risk factors for MAUD+ASPD, and the impact of this dual diagnosis on severity and 
functioning, may allow for the development of more targeted treatment strategies that can 
enhance retention and outcome. 
 
1.1  Research Aims and Objectives 
The primary aim of this study was to describe and compare sociodemographic profiles, 
clinical correlates of illness severity and psychosocial impairment, and CT histories between 
patients with MAUD+ASPD and MAUD without ASPD (MAUD-ASPD).  It also aims to 
determine the contribution of these variables in predicting the MAUD+ASPD dual diagnosis.  
Several objectives were identified:   
 
Objective 1:  To explore and compare sociodemographic variables, such as age, gender, 
ethnicity, and level of education, between MAUD+ASPD and MAUD-ASPD. 
Objective 2:  To compare rates of CT between patients with MAUD+ASPD and those with 
MAUD-ASPD. 
Objective 3:  To compare the severity of CT between patients with MAUD+ASPD those 
with MAUD-ASPD. 
Objective 4:  To compare illness severity and psychosocial disability between patients with 
MAUD+ASPD and those with MAUD-ASPD. 
Objective 5:  To determine whether MAUD+ASPD membership (as opposed to MAUD-





1.2  Structure of Dissertation  
In addition to Chapter One, this thesis comprises four chapters:  
1. Chapter Two is a literature review that appraises both international and local research 
on MAUD and ASPD with associated illness severity and psychosocial functioning.  
It also reviews literature of CT in relation to MAUD and ASPD.   
2. Chapter Three presents the methodology that was followed in conducting this 
research.  It also includes a discussion of ethical considerations related to the study. 
3. Chapter Four reports on the findings of the study. 
4. Chapter Five presents a discussion of the findings by drawing on existing literature in 
the field.  The chapter also concludes by exploring possible limitations of this 


























This chapter will review exiting literature available on methamphetamine use disorder 
(MAUD) and antisocial personality disorder (ASPD), as well literature on the comorbidity of 
these diagnoses.  By drawing on international and local research, this chapter will also 
explore illness severity and psychosocial impairment in patients with MAUD.  The role of 
childhood trauma (CT) in both MAUD and ASPD will then be reviewed.   
  
2.1  Methamphetamine Use Disorder (MAUD)  
2.1.1  Methamphetamine  
Methamphetamine (MA) is a synthetic substance that is also known as “speed”,  “meth”, 
“ice”, “crystal”, “glass”, (Aronson, 2016) or “tik”, as it is most commonly referred to in 
South Africa (Plüddemann et al., 2013).  It is a white odourless crystal-like substance 
(Plüddemann et al., 2013) and falls within the drug class of amphetamines (Yen & Chong, 
2006).  Methamphetamine is considered as a more potent form of amphetamine (Yen & 
Chong, 2006) and is a powerful psychoactive stimulant (Plüddemann et al., 2013).  Usually, 
it is compounded in powder or pill form and can be taken orally (swallowing or smoking), 
intranasally (snorting), or intravenously (injecting) (Plüddemann et al., 2013).  Locally, MA 
is relatively cheap and available – making it an attractive choice for users (Watt et al., 2014).    
 
2.1.2  Methamphetamine Use Disorder 
Methamphetamine use is increasing both globally (Meredith et al., 2005) and nationally 
(Plüddemann et al., 2013) and there is a need to understand both the causes and the impact of 
this fast-growing epidemic (Watt et al., 2014).  Methamphetamine use disorder is a 
psychiatric condition characterized by a pattern of MA use that results in significant 
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impairment and/or distress on multiple levels of functioning (APA, 2013).  Individuals with 
MAUD will often neglect major obligations such as occupational, family, recreational, and 
social responsibilities or activities.  They also spend vast amounts of time obtaining, using, or 
recovering from the effects of MA use.  Furthermore, patients often demonstrate a disregard 
for the negative consequences or problems that are caused or exacerbated by MA use and 
may even use MA in hazardous situations such as when they are driving (APA, 2013).  
Another hallmark of MAUD is repeated unsuccessful attempts to cut down or stop MA use 
(APA, 2013). 
According to the South African Community Epidemiology Network on Drug Use 
(SACENDU), MA is a common substance of abuse locally and almost a third of all patients 
from addiction treatment centres in the Western Cape are patients who receive treatment for 
MA use-related problems (Dada et al., 2017).  In general, it appears that locally substance use 
seems to be associated with contexts of historical oppression and economic marginalization 
(Chetty, 2015).   
Internationally, different and inconsistent patterns of MA use between genders have 
been found (Cohen et al., 2007; Simpson et al., 2016), but locally it appears that MA is 
slightly more common among males (Watt et al., 2014).  Sociodemographic research suggest 
that MA use is especially high among the ‘coloured’1 or mixed-race population and it is 
commonly used by younger individuals with lower levels of educational attainment 
(Cservenka & Ray, 2017; Polcin et al., 2012; Semple, Zians, Grant, & Patterson, 2005; Watt 
et al., 2014).  Often users are separated or single, and occupation status varies with men more 
often having employment compared to women (Cohen et al., 2007).  Female with MAUD 
often have lower levels of education, are unemployed or underemployed (Cohen et al., 2007).   
 
1 The term ‘coloured’ was used as a racial classification category under the Population Registration 
Act of the previous dispensation and is still commonly used in South Africa today to refer to 
individuals who are of mixed race (Adhikari, 2009). 
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In conclusion, MA is a powerful psychoactive stimulant with potent reinforcing 
effects and potential for misuse (Aronson, 2016).  Over time and prolonged use may lead to 
pharmacological dependence that is characterized by (increased) tolerance to the effects of 
MA and withdrawal when reducing or stopping use (APA, 2013).  Methamphetamine 
withdrawal is marked with more psychiatric manifestations, rather than somatic symptoms, 
and typically includes states of depression, severe dysphoria, anxiety, irritability and 
aggression, and paranoia (Meredith et al., 2005) that may exacerbate dysfunction and distress 
(APA, 2013). 
 
2.1.3  Impact of Methamphetamine Use  
The use of amphetamine-like substances, such as MA, is associated with a variety of 
physiological and medical sequela.  When MA is administered, the initial physiological 
response includes increased physical functioning, reduced appetite, increased arousal, and 
restlessness (Watt et al., 2014).  In contrast to the acute effects of MA intoxication, various 
medical sequela may arise from the prolonged use of MA.  The most common are cardiac 
problems which include tachycardia, dysrhythmias, cardiomyopathy, cardiomegaly, and 
pulmonary oedema which have often been associated with inhalation (smoking) of MA 
(Aronson, 2016).  Longstanding evidence suggests that the use of amphetamines like MA is 
associated with intracerebral haemorrhage and stroke (Aronson, 2016) which could be fatal.  
Changes in blood pressure and body temperature are common during use and in some cases 
may lead to hyperthermia that can result in convulsions, cardiovascular collapse, and death 
(Richards & Laurin, 2017).  Other medical problems include increased risk for infections, 
skin problems, and immune-system disorders (Aronson, 2016) and severe dental decay, 
known colloquially as ‘meth-mouth’.  
21 
 
When MA is administered there is a surge in the release of dopamine from nerve 
terminals which results in central nervous stimulation that induces a state of euphoria 
(Aronson, 2016).  The acute effects of intoxication (often called a ‘high’) produce a sense of 
exhilaration with increased self-esteem, improved mental functioning, violent and aggressive 
behaviour, and extended wakefulness (Watt et al., 2014).  Amphetamine-like substances 
release monoamines in the brain and thereby stimulate noradrenergic, serotonergic, and 
particularly dopaminergic receptors (Aronson, 2016).  In contrast to the euphoric and 
exhilarating affects of neurotransmitter release, chronic use of MA often leads to long-lasting 
neurological changes that may result in amotivational and psychiatric problems - even after 
use has stopped (Aronson, 2016).  Neurological disorders in amphetamine and MA-using 
populations may include stereotypic movement disorders and motor-functional problems, 
chorea, and dyskinesia (Meredith et al., 2005).  Stereotypic movement disorders are 
involuntary/automatic behaviours which may last for hours on end.  These may include 
chorea or dyskinesia that includes strange facial and tongue movements or jerky motions of 
the arms and legs and a never-ending repetition of certain actions.  Since significant 
reductions in dopamine transporters occur both with age and MA use, it is likely that MA use 
leads to a higher risk of Parkinsonian symptoms in abusers later in life (Aronson, 2016). 
Some with MAUD may develop both acute and/or chronic psychosis – often referred 
to as MA-psychosis.  These often include auditory and/or visual hallucinations that are 
similar to those experienced in paranoid schizophrenia (Aronson, 2016).  Methamphetamine 
use has also been associated with secondary mental health problems.  Psychiatric 
comorbidities may arguably be seen as a predisposition for, or perhaps a consequence of, 
continued drug use (Yen & Chong, 2006) and may include anxiety, depression, poor 
attention, and impaired executive functioning (Watt et al., 2014).  Research to date has shown 
that depressive symptoms are frequently associated with MA use (Kalechstein et al., 2000; 
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Salo et al., 2011) and the prevalence of trauma- and stressor-related disorders [such as post-
traumatic stress disorder (PTSD)] and anxiety disorders (social anxiety disorder, panic 
disorder, and agoraphobia) associated with MAUD may also be high (Akindipe et al., 2014). 
Beyond the individual, MA use has been associated with various problems with inter-
personal relationships and at community level (Polcin et al., 2012; Watt et al., 2014).  Taking 
into account the psychological and behavioural effects and the lifestyle characteristics of 
individuals with MAUD, it has often been linked to relational problems, including violence, 
intimate partner or domestic abuse, crime, and community cohesion deficits (Watt et al., 
2014).  On a societal level, MA use places a significant financial burden on families and 
communities (Watt et al., 2014), as well as the health system (Polcin et al., 2012).  
Furthermore, MA use has a major impact on the economy as it fuels reduction in 
productivity, environmental damage, extra law enforcement, and additional healthcare 
expenses (Polcin et al., 2012).  As in other countries, MAUD in South Africa is associated 
with a broad range of negative health issues, including HIV sexual transmission behaviours, 
HIV seroconversion and mental disorders (e.g. mood and psychotic disorders) (Okafor et al., 
2020). 
As mentioned earlier, MA is a potent psychoactive stimulant and experimental, 
recreational, or chronic use often results in the rapid development and onset of MA 
dependence/MAUD.  Users are often caught in a cycle that is hallmarked by an inability to 
cut down or to stop MA use.  Physical, as well as psychological dependence are often 
accompanied with discomfort and it is common for users to administer MA almost daily or 
even a few times a day to avoid distress (APA, 2013).   
Methamphetamine use and MAUD often have a poor prognosis.  Literature highlights 
varied treatment success, with high treatment drop out and relapse (Cohen et al., 2007; Polcin 
et al., 2012).  As seen earlier, individuals who use MA often have comorbid physiological 
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(Aronson, 2016), psychological or emotional problems (Watt et al., 2015), as well as social 
constraints (Watt et al., 2014) that are caused and/or exacerbated by MA use which impacts 
functioning (APA, 2013). 
   
2.1.4  Illness Severity and Psychosocial Disability 
There are relatively few studies that investigate illness severity and psychosocial functioning 
in populations with a primary diagnosis of MAUD.  However, it has been suggested that 
psychosocial functioning is negatively affected by MA use (Gonzales et al., 2011; Lecomte et 
al., 2010).  Psychosocial functioning is often significantly impaired on and populations that 
use MA often have poor quality of life (Gonzales et al., 2011; Grant et al., 2010).  One local 
study found that that people using MA are at high risk for problems related to psychosocial 
functioning (Berg et al., 2017).  Grant et al. (2010) adds that moderate psychosocial 
dysfunction can be found among people with MAUD. 
Methamphetamine use and MAUD may also lead to significant illness severity.  One 
study suggests that people that use MA may present with marked illness severity (Grant et al., 
2010).  Another study stresses that illness severity in this population can be very high, and in 
some cases, MA use may result in mandatory hospital admission due to illness severity 
(Eslami-Shahrbabaki et al., 2015).  Recent pleas have also highlighted the need for research 
on illness severity in patients with MAUD (Eslami-Shahrbabaki et al., 2015).  Some authors 
suggest that there is little difference in illness severity between genders in populations that 
use MA (Grant et al., 2010) but findings are inconsistent (Simpson et al., 2016), with some 
studies suggesting that women have the highest MA use illness severity (Simpson et al., 





2.2  Antisocial Personality Disorder (ASPD) 
Antisocial personality disorder is a psychiatric diagnosis classified among the personality 
disorders in the Diagnostic and Statistical Manual of Mental Disorders – fifth edition (DSM-
5) (Conti, 2016; APA, 2013).  Personality disorders constitute a group of inflexible and 
pervasive mental health conditions that are characterized by an enduring pattern of inner 
experience and behaviour that distinctly differs from the cultural expectations of/for an 
individual (APA, 2013).  More specifically, ASPD is characterized by a continuous disregard 
for, as well as the violation of, the rights and safety of others (APA, 2013).  Individuals with 
ASPD often fail to conform to societal expectations of lawful behaviour.  Often they are 
characterized as irresponsible in terms of work or financial responsibilities (APA, 2013).  
Furthermore, individuals with ASPD typically present with irritability, aggressiveness, and 
impulsivity.  Other hallmarks of this disorder are being deceitful, lying, using aliases, or 
conning others for self profit or pleasure (APA, 2013).  Individuals with ASPD may also 
demonstrate a lack of remorse, as indicated by being indifferent to the realization of hurting, 
mistreating or stealing from others (APA, 2013).  According to the DSM-5 (APA, 2013), in 
order to meet a diagnosis of ASPD, one must be at least 18 years old, have a history of 
conduct disorder, and meet three of the following criteria: 1) failure to conform to social 
norms; 2) deceitfulness; 3) impulsivity; 4) irritability and aggressiveness; 5) reckless 
disregard for safety of self or others; 6) consistent irresponsibility; and 7) lack of remorse 
(Conti, 2016). 
Psychiatric epidemiological studies in South Africa are limited and often do not report 
on the prevalence of personality disorders (Stein et al., 2008).  Statistics on ASPD in South 
Africa’s general population are also limited.  International figures indicate that ASPD is 
present in around 3.5% of the general population (Salyer, 2007).  Most studies that report on 
ASPD are conducted in special populations, such as prison settings (e.g. Loots & Louw, 
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2012), people with substance use disorder or psychiatric populations (Waumsly, 2007).  In 
one small study done locally in a psychiatric hospital in the Western Cape, Waumsly (2007) 
found that ASPD is one of the most frequently diagnosed personality disorders among 
discharged psychiatric patients with figures indicating prevalence rates of 29%.  This was 
notably higher compared to rates of other personality disorders in these patients, such as 
borderline personality disorder and histrionic personality disorder (Waumsly, 2007).  
Antisocial personality disorder is more common among males, younger age groups between 
the ages of 25-44 years, and individuals with low academic attainment (Holzer & Vaughn, 
2017) and who are single (Salyer, 2007).  
 
2.2.1. Comorbidity of Methamphetamine Use Disorder and Antisocial Personality 
Disorder 
There is ample international research to suggest that ASPD is common among people with 
substance use disorders generally.  In fact, ASPD is one of the two most consistently reported 
personality disorders in subjects with substance use disorders (SUDs) (Le Bon et al., 2004).  
One study found that ASPD is higher in populations with SUDs than compared to the general 
population (Compton et al., 2005).     
Several models may explain ASPD comorbidity in SUDs.  The comorbidity of 
MAUD and ASPD might be attributed to common underlying features, such as personality 
characteristics like impulsivity (APA, 2013; Dellazizzo et al., 2018), genetic, behavioural and 
cognitive factors (Rzhetsky et al., 2007; Smith et al., 2014), or shared risk markers for 
externalizing behaviours (Brook et al., 2016; Trull et al., 2000).  It is also possible that the 
presence of personality pathology creates increased risk for substance use, for example as an 
emotion regulation strategy (Verheul, 2001).  As mentioned earlier, locally MA is relatively 
cheap and an attractive substance of abuse.  Individuals with ASPD may be more likely to 
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drop out from school, experience trouble with the law, and engage with peers that can expose 
them to illicit substance use.  In a study by Meade et al. (2014) respondents linked tik use to 
increased rates of crime, violence and corruption, which undercut community cohesion, 
accompanied by antisocial behaviours (Cohen et al., 2007), which may be induced by the 
neurological and psychological impact of the substance.   
In addition to the common comorbidity of ASPD in SUDs generally, it is well 
documented that ASPD often occurs comorbidly in populations that use MA (Fletcher & 
Reback, 2013; Lecomte et al., 2010; Plüddemann et al., 2013).  However, if the onset of MA 
abuse is before the age of 15 years (the age by which ASPD symptoms need to have been 
present), it may be difficult to distinguish the effects of MA abuse from an emerging 
antisocial personality disorder.   
Prevalence rates of this dual diagnosis seem to vary in the literature, with a prevalence 
range between five to 68% (Fletcher & Reback, 2013; Lecomte et al., 2010; Plüddemann et 
al., 2013).  It appears that little is yet known about risk factors for the development of this 
dual diagnosis.  There is some research on the clinical implications of MAUD+ASPD, but it 
is still quite limited.  A comorbid diagnosis of ASPD in MAUD may be associated with 
heavier MA use (Lecomte et al., 2010) and reduced prosocial or health-related behaviours 
(Fletcher & Reback, 2013).  Heavier MA use may also impact treatment-seeking efforts (Lin 
et al., 2004), which in return can result in increased psychiatric and physiological sequela 
(APA, 2013; Callaghan, Cunningham, Sykes, & Kish, 2012; Meredith et al., 2005).  Where 
personality pathology such as ASPD is comorbid with MAUD, there may be greater clinical 
complexity and poorer prognosis (Kalechstein et al., 2000; Martens, 2000) which may often 
necessitate specialized assessment and intervention.  It has been suggested that screening for 
deviant personality patterns like ASPD may be warranted in individuals with MAUD during 
admission for detoxification and rehabilitation as some research shows that people MAUD 
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with comorbid ASPD are more likely to relapse to heavy MA use after treatment (Fridell et 
al., 2006).  Investigation of ASPD patterns in MAUD may improve our understanding of the 
development from MA use to dependence and addressing ASPD in MAUD and may help to 
decrease or even prevent development from MA use to MA dependence (Zhang et al., 2018).   
 
2.3  Childhood Trauma (CT) 
Childhood trauma is common in the South African context and high rates of at least one 
traumatic event during lifetime has been reported in local cohorts (Hobkirk et al., 2015; 
Kaminer et al., 2013; Williams et al., 2007).  Childhood trauma can be defined as exposure to 
traumatic events during childhood that result in adverse developmental consequences 
(Busuttil, 2009; Gregorowski & Seedat, 2013).  It is often conceptualized in terms of 
physical, sexual and emotional maltreatment or abuse that occurs within the context of a child 
and attachment or caregiver relationships (Bernstein et al., 2003; Norman et al., 2012).  
Trauma that occurs during childhood and adolescence can alter transition into adulthood due 
to social, behavioural, physiologic, and neurobiological changes that cascade from such 
adversity and is associated with a significantly increased risk of mental health difficulties 
(Anda et al., 2006; Hatcher et al., 2019).    
 
2.4  Childhood Trauma, Methamphetamine Use Disorder and Antisocial Personality 
Disorder 
Research to date has demonstrated that different types of CT frequently occur concurrently 
and that it confers the risk for multiple psychiatric diagnoses (Keyes et al., 2012), including 
substance use and personality disorders in adulthood (Machisa et al., 2016).  More 
specifically, it has been associated with both MAUD (Lecomte et al., 2010; Lopez-Patton et 
al., 2016; Svingen et al., 2016) and ASPD (Berenz et al., 2013; Bierer et al., 2003; Haller & 
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Miles, 2004; Lecomte et al., 2010).  Literature suggests that people with MAUD with a 
history of CT have increased risk for a comorbid diagnosis of ASPD (Lecomte et al., 2010) 
and Messina et al. (2008) found that populations who use MA and who have a diagnosis of 
ASPD report greater experiences of childhood abuse compared to those without ASPD.  
However, research that specifically explores CT in samples with a primary diagnosis of 
MAUD and comorbid ASPD seems to be scant and no South African research to date has 
examined this.  This section provides an overview of current literature on the relationship that 
CT may have with MAUD and ASPD.  
 
2.4.1  Childhood Trauma and Methamphetamine Use Disorder 
Childhood trauma can profoundly affect mental health (Carliner et al., 2016; Hatcher et al., 
2019) and substance use is often a mechanism or an attempt to cope with the lasting impact  
thereof (Berg, Hobkirk, Meade, & Joska, 2017; Watt, Myers, Towe, & Meade, 2015).  
Individuals with a history of CT are at greater risk of developing substance use problems 
during adolescence and in adulthood than those without such histories (Svingen et al., 2016).   
It has been suggested that between 40 and 90% of people with substance use disorders 
report a history of CT (Banducci et al., 2014; Kendler et al., 2000).  Sexual abuse (Cuellar & 
Curry, 2007; Dong et al., 2004; Kendler et al., 2000; Vera et al., 2005), physical abuse and 
neglect (Dong et al., 2004; Mersky et al., 2013; Svingen et al., 2016), and emotional trauma 
(Svingen et al., 2016) during childhood have all been associated with substance use problems 
(Hogarth et al., 2019) and the development or onset of a SUD.  Contextual factors such as the 
age when the trauma is experienced, or the frequency thereof, may also impact psychological 
functioning/development (van der Kolk, 2003) and increase the risk for substance abuse 
(Lieberman et al., 2011).   
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Childhood trauma is common in populations that use MA (Ding et al., 2014; 
Lanesman et al., 2019).  However, there is a paucity of empirical studies investigating the 
relationship between CT and MA use in adulthood (Lopez-Patton et al., 2016).  Some 
literature indicates that a wide range of childhood abuse, including sexual, emotional, and 
physical abuse, is significantly higher in patients who use MA compared to non-MA-users 
(Lopez-Patton et al., 2016).  It has also been suggested that women, compared to men, report 
the most extensive histories of childhood abuse in MAUD populations (Messina et al., 2008).  
Little research that focuses on childhood physical trauma has been conducted in samples with 
a primary diagnosis of MAUD, warranting further exploration.  There is evidence to suggest 
that childhood physical trauma is significantly more prevalent among substance-abusing 
males (Dong et al., 2004; Khoury et al., 2010; Svingen et al., 2016).  This contrasts to the 
finding that  MA using females are almost twice as likely as their male counterparts to report 
physical abuse during childhood and adolescence (Messina et al., 2008).  In one study done 
with MA using participants, physical abuse was reported by 64% of women and 36% of men 
(Cohen et al., 2007).   
Emotional trauma during childhood has been associated with substance use problems 
in both men and women (Hogarth et al., 2019; Dong et al., 2004).  One study reports that 
84% of women and 64% of men in their sample of participants who use MA reported 
histories of emotional abuse (Cohen et al., 2007).   
Local studies that report on the prevalence of childhood sexual abuse among people 
with MAUD are limited.  Nevertheless, it appears as if individuals with a history of MA use 
have increased histories of sexual abuse in comparison with the general population.  In a 
review of lifetime abuse in patients with MAUD it was indicated that 29% of women and 7% 
of men reported sexual abuse (Cohen et al., 2007) during childhood.  One local study with 
patients seeking treatment for problems associated with MA use suggested that childhood 
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sexual abuse was more than twice as prevalent in women who use MA compared to those 
who do not (Berg et al., 2017).  The study also found histories of sexual abuse in 45% of 
women and 20% of men with MAUD (Berg et al., 2017).   
 
2.4.2  Childhood Trauma and Antisocial Personality Disorder 
Childhood trauma is associated with personality disorders in adulthood (Kounou et al., 2013) 
and has strong associations with ASPD in particular (Berenz et al., 2013; Semiz et al., 2007; 
Sher et al., 2015).  Specific forms of trauma including a history of sexual abuse, physical 
abuse (Sher et al., 2015) and emotional abuse have all been associated with antisocial 
behaviour (Riggs & Kaminski, 2010).  More specifically, a history of sexual abuse and 
physical abuse predicts ASPD in males, whereas sexual abuse, combined sexual and physical 
abuse, but not physical abuse alone, predict ASPD for females (Sher et al., 2015).  Most of 
the research has focused on high-income countries and little is known about the relationship 
between CT and personality disorders in low and middle-income settings like South Africa 
(Kounou et al., 2013).  Although CT is strongly associated with both MAUD and ASPD, the 
role of CT in creating risk for MAUD with ASPD comorbidity is vague.  It is possible that 
specific types or increased severity of CT experiences may enhance the risk for this dual 
diagnosis. 
 
2.5  Conclusion 
Methamphetamine use is very common in South Africa with some authors suggesting that it 
has reached epidemic proportions.  Methamphetamine use disorder holds devastating 
physiological, psychological and social sequela for the user and the community.  Little is 
known about potential risk factors for the dual diagnosis of MAUD and ASPD, and the 
impact of this comorbidity on both the severity of MAUD and levels of functional 
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impairment and according to our knowledge South African research have not been conducted 




























3.1  Research Design  
This study has a cross-sectional and descriptive correlational design and formed part of a 
broader project which is largely quantitative in nature.  The present study is a secondary 
analysis of data collected by the South African Medical Research Council’s Unit on Risk and 
Resilience in Mental Disorders, a cross-university facility between Stellenbosch University 
(SU) and the University of Cape Town (UCT) (hereafter referred to as the SA MRC Unit).  
All the data analysed for this research project were sourced from the SA MRC Unit’s on-
going project, named “Gambling Disorder and Methamphetamine Use Disorder: A 
neurocognitive, genetic and neuroimaging study”.  The parent project was launched in 
September 2015 and was funded by the South African National Research Foundation (SA 
NRF).   
The aim of the overarching project is to investigate the role of polymorphisms in 
specific candidate genes that account for differences in brain-imaging, cognitive-affective 
performance, and performance in behavioural tasks of patients with (primary diagnoses) of 
gambling disorder and methamphetamine use disorder (MAUD).  It received ethics approval 
from SU (reference number N14/05/053) and UCT (reference number 770/2014).  It must be 
noted that most of the methodological aspects, of the current research project, such as the 
recruitment of participants, data collection, and ethical considerations, were based on the 
overarching study’s methodology and protocol.   
 The current research project was explorative and descriptive in nature.  Exploratory 
and descriptive research is usually conducted when there is insufficient research available on 
a particular subject and aims to understand a phenomenon to develop preliminary ideas or to 
refine future research related to causality (Blaikie, 2003).  For the current research study, the 
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researcher only included data from those measures relevant to the aim and objectives of the 
study and to my knowledge no research with the specific aims and objectives of this study 
have yet been conducted.  It must be noted that the researcher and author of this study 
recruited participants and conducted interviews with such recruits. 
 
3.2  Research Questions 
As stated in Chapter One, the aim of the study was to compare sociodemographic variables 
and clinical severity, and histories of childhood trauma (CT) between MAUD with comorbid 
antisocial personality disorder (MAUD+ASPD) and MAUD without ASPD (MAUD-ASPD).  
Sociodemographic variables investigated here included age, ethnicity, gender, and level of 
education.  Clinical severity included both illness severity and levels of psychosocial 
impairment.  Childhood trauma history included exposure rates and severity of physical, 
sexual and emotional abuse, and emotional and physical neglect.  The study aimed to answer 
the following research questions:  
1. Are there sociodemographic differences between patients with MAUD+ASPD and 
patients with MAUD-ASPD?   
2. Are there differences in illness severity and psychosocial disability between the two 
groups? 
3. Are there differences in overall CT exposure, as well as the rates and severity of 
specific forms of trauma, between the two groups?   
4. Can group membership (i.e. MAUD+ASPD vs. MAUD-ASPD) be predicted by any 






3.3  Sample 
Recruitment of participants for the overarching study started in September 2015.  Only 
individuals with a history of and/or current methamphetamine (MA) use were recruited.  
Males and females were recruited from the community through newspaper advertisements.  
In the advertisements, the researcher, who is the author of this dissertation, provided contact 
details for potential participants to respond to.  Participants were also recruited from 
addiction treatment centres (inpatient and outpatient) or practitioners (private and 
governmental) who provide services to individuals with substance use problems 
(methamphetamine) in the Western Cape Province. 
 Individuals from the community who responded to newspaper advertisements were 
contacted by the research assistants that work on the overarching project.  Participants that 
were recruited from local treatment centres or other treating professionals were screened by 
the referral practitioner prior to referral to the study.  With patient permission, the treating 
professionals provided research assistants with contact details to contact their referrals.  All 
prospective participants with a history of and/or current MA use were contacted either by 
telephone, e-mail, or WhatsApp to schedule a semi-structured interview to determine if they 
could be included in the research project.  Inclusion criteria were 1) having a primary life-
time diagnosis of MAUD, 2) aged between 18 and 65 years, 3) and residing in the Western 
Cape Province of South Africa.  Because other psychiatric problems and poly-substance use 
are rife in MA using populations, individuals with a history of comorbid mental illnesses or 
additional substances were also allowed to participate in the study.  
 
3.4  Instruments    
All instruments used in this study were offered in both Afrikaans and English, depending on 
the participants’ language preference.  For measures that were not available in Afrikaans, 
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translation was done by the MRC from English to Afrikaans and these received approval by 
both ethics’ committees at UCT and SU.  For this study the following assessments were 
included in the data analysis:  
Demographic characteristics.  The sociodemographic questionnaire that was used in the SA 
MRC Unit’s study was administered to each participant at the beginning of the interview.  
The questionnaire recorded the following sociodemographic information:  the participant’s 
age, level of education, occupational status, gender, and language.  The questionnaire can be 
found in the appendices as “Appendix A”. 
SCID – 5.  The Substance Use Disorder module of the Structured Clinical Interview for 
DSM-5 Disorders (SCID-5) was administered to all participants.  It has often been used in 
research to diagnose substance use disorders (SUDs) such as MAUD (Lopez-Patton et al., 
2016; Ogloff et al., 2015) and has also been used reliably in South African research (e.g. Mall 
et al., 2014).  The SCID-5 (module E) measures symptoms of a wide variety of substance use 
that included stimulant-like substances (such as MA) on a severity scale comprising of 11 
questions, with each item receiving a score out of three.  The SCID-5's severity scale has 
demonstrated good internal consistency (Cronbach's αs > 0.80), test–retest reliability, and 
concurrent, incremental and predictive validity (Shankman et al., 2018).  The psychometric 
properties of the SCID-identified symptom scales have been shown to be far superior to other 
psychometric tests that consist of categorical diagnoses for both current and lifetime 
psychopathology (Shankman et al., 2018).  The substance use disorder module of the SCID-5 
can be found in the appendices as “Appendix B”. 
MINI.  The Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1994) was 
used to assess the diagnostic status of ASPD.  The MINI’s ASPD module is divided into two 
sections based on the DSM-5 (American Psychiatric Association (APA), 2013) diagnostic 
criteria.  Each section has six yes-no-questions relating to specific antisocial behaviours. The 
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first section focuses on specific behaviours prior to the age of 15 years.  If two or more 
questions are answered as “yes” in this section, the interviewer continues with the second 
section of questions regarding antisocial behaviours after the age of 15 years.  If three or 
more questions were answered as “yes” in this section, a diagnosis of ASPD is met.  The 
MINI as a whole has good reliability and validity (Sheehan et al., 1998) and has been used in 
both international (Sulaiman et al., 2014) and local (Akindipe et al., 2014) research on 
MAUD.  A copy of the ASPD module of the MINI can be found in the appendices as 
“Appendix C”. 
CTQ-SF.  The Childhood Trauma Questionnaire Short Form (CTQ-SF) (Bernstein et al., 
1994) was used to assess exposure to different forms of CT.  The CTQ-SF is one of the most 
widely used and investigated measures of diverse forms of childhood maltreatment 
(Spinhoven et al., 2014).  The CTQ-SF is a self-report measure used to assess both the nature 
and severity of CT.  The CTQ-SF comprises of 28 Likert-type items, with five response 
options, ranging from “never true” to “very often true” and asks questions related to 
traumatic events in the childhood and adolescent years.  The CTQ-SF is divided into 
dimensional scales to enhance reliability and maximize statistical power (Bernstein et al., 
2003).  Subscales of the CTQ-SF include measures of emotional abuse, physical abuse, 
sexual abuse, emotional neglect and physical neglect (Bernstein et al., 2003; Oh et al., 2018; 
Spinhoven et al., 2014).  Each scale consists of five items that are scored on the 5-point 
Likert-type scale ranging from five to 25 (Grassi-Oliveira et al., 2014; Spinhoven et al., 
2014).  The severity of abuse and neglect are determined according to cut-off scores: none to 
minimal, low to moderate, moderate to severe, and severe to extreme (Grassi-Oliveira et al., 
2014).  According to the manual the recommended cut off scores are emotional abuse: none 
to minimal = 5-8; low to moderate = 9-12; moderate to severe = 13-15; severe to extreme = 
16+, physical abuse: none to minimal = 5-7; low to moderate = 8-9; moderate to severe = 10-
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12; severe to extreme = 13+, sexual abuse: none to minimal = 5; low to moderate = 6-7; 
moderate to severe = 8-12; severe to extreme = 13+, emotional neglect: none to minimal = 5-
9; low to moderate = 10-14; moderate to severe = 15-17; severe to extreme = 18+, and 
physical neglect: none to minimal = 5-7; low to moderate = 8-9; moderate to severe = 10-12; 
severe to extreme = 13+ (MacDonald et al., 2016).  Total scores and severity of CT on the 
CTQ are interpreted as follows: none/minimal (< = 36), low to moderate (> 36 and < = 51), 
moderate to severe (> 51 and < = 68), and severe to extreme (> = 69) (MacDonald et al., 
2016).  To minimize socially desirable responses of false-negative trauma reports, three 
additional items are included in a minimization scale (Spinhoven et al., 2014).   
The CTQ-SF can be used in adult populations (Bernstein et al., 2003; Oh et al., 2018).  
Reliability and validity of the CTQ-SF have been well established in both substance use 
populations and psychiatric populations with personality pathology (Bernstein et al., 2002), 
with good evidence of criterion-related validity in these subgroups (Bernstein et al., 2003; 
Spinhoven et al., 2014).  It has been used in the South African context (e.g. Brooks et al., 
2014; Hogarth et al., 2019; Lochner et al., 2005, 2008) with acceptable internal consistency 
(Cronbach's αs 0.70) (Brooks et al., 2014).  Further, the CTQ-SF is quick to administer, 
usually not taking more than five minutes to complete (Bernstein et al., 2003), which made it 
ideal considering the extensive test battery of the overarching project.  A copy of the CTQ-SF 
is attached in the appendices as “Appendix D”. 
Y-BOCS-du.  The Yale-Brown Obsessive Compulsive Scale adapted to reflect obsessions 
and compulsions related to drug use (Y-BOCS-du) (Goodman et al., 1989) was used to assess 
MA use severity.  The Y-BOCS-du was adapted from the Yale-Brown Obsessive-
Compulsive Scale (Y-BOCS) and Yale-Brown Obsessive-Compulsive Scale for Heavy 
Drinking (Y-BOCS-hd) and has been used in research with MA using participants (Eslami-
Shahrbabaki et al., 2015).  Similar to the Y-BOCS-hd, it measures obsessive-compulsive 
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characteristics of substance-using individuals (Friedman, Dar, & Shilony, 2000).  The 
questionnaire specifically measures the severity of obsessionality and compulsivity related to 
substance use (Friedman et al., 2000).  For this research project, the Y-BOCS-du was adapted 
to measure obsessionality and compulsivity of MA using individuals.  The changes to Y-
BOCS-du to assess MA use severity were limited, with only the words referring to alcohol 
use, adapted to refer to MA use.  
The Y-BOCS-du is similar to the original Y-BOCS and comprises a 10-item clinician-
rated scale.  The scoring system is also identical to that of the original Y-BOCS.  Each item is 
rated from 0 (no symptoms) to 4 (extreme symptoms).  Items 1 to 5 comprise the 
obsessionality subscale and reflect MA-related thoughts; items 6 to 10 comprise the 
compulsivity subscale and reflect MA-related behaviours.  The total score of the 
questionnaire is the sum of all 10 items with each subscale having a range of 0 to 20 and a 
total range of 0 to 40 (Friedman et al., 2000).  The internal consistency of the Y-BOCS-du is 
good (Cronbach's αs 0.70) (Friedman et al., 2000).  A total score of 10 to 20 indicates mild-, 
21 to 30 indicates moderate-, and 31 to 40 indicates severe illness severity based on obsessive 
and compulsive symptoms (Boyette et al., 2011).  A copy of the Y-BOCS-du can be found in 
the appendices as “Appendix E”.  
SDS.  The Sheehan Disability Scale (SDS) (Sheehan et al., 1996) is a self-report measure to 
assess the severity of psychosocial disability.  The SDS comprises of three Likert style items 
on a discretized analogue scale to indicate the degree of impairment in the domains of work, 
family and social life (Olley et al., 2005; Sheehan & Sheehan, 2008).  The higher the scores, 
the greater the psychosocial impairment and disability (Olley et al., 2005).  Ranges of each 
domain are described as follow: zero = no impairment; one to three = mildly impaired; four 
to six = moderately impaired; six to nine = markedly impaired; and 10 = extremely impaired 
(Rush et al., 2008).  The three items of the measure can be summed to provide a global score 
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(SDS total score) of functional impairment that ranges from zero (no impairment) to 30 
(highly impaired) and converted into a total percentage (Rush et al., 2008).  The 
psychometric properties have been found to be satisfactory (Hodgins, 2013) and it has been 
used in populations of MAUD and patients with psychiatric problems locally (Olley et al., 
2005) and internationally (Glasner-Edwards et al., 2008).  The SDS is attached in the 
appendices as “Appendix F”.   
3.5  Procedures 
After recruitment, each participant was asked to attend a semi-structured interview for 
psychometric evaluation with research assistants working for the SA MRC Unit.  On arrival, 
each participant provided informed consent before data collection started.  Subsequently, 
each participant (together with the researcher) completed psychometric tests and self-reports.  
The majority of data collection was conducted at the SA MRC Unit sites, based in the 
Department of Psychiatry at SU or UCT.  Participants recruited from the community selected 
which site they preferred to attend (based on distance from home, ease of access, the 
availability to travel, etc.).  To meet the needs of participants who were recruited from local 
treatment centres or other practitioners, they were either seen at the respective 
facility/organization or at a SA MRC Unit site.  All interviews took place in a private 
consultation room and refreshments such as coffee, tea, or water were offered when the 
participant arrived.  The researchers are fluent in Afrikaans and English and the interviews 
were conducted in the language preferred by the participant. 
The researchers received training to administer the battery of psychometric tests and 
worked under the supervision of a clinical psychologist to discuss assessment results of 
diagnostic measures such as with the SCID 5 and MINI.  Most of the interviews lasted for 




3.6  Data Analysis  
After data collection ended, all data were entered into an electronic database (SPSS 
software).  Any identifying information of the participants was removed and an anonymized 
database was used for data mining.  A total of 110 participants were included when data 
collection for this study ended.  However, only 62 participants were included in the analysis.  
Reasons for exclusion were an absence of MAUD as a primary diagnosis.   
During data analysis, the scores of each assessment were calculated and entered in the 
database.  Sub-scale-scores of the CTQ-SF were calculated by applying syntax developed for 
the measure in the electronic database.  The rates of CT (i.e. absence vs. presence) were 
manually calculated by examining total scores of the CTQ-SF.  The minimum score that 
could be obtained on the CTQ-SF was 25 (absence).  If a score greater than 25 was obtained, 
a history of CT was inferred.  The different sub-scales with minimum scores of five were 
examined to determine the absence versus the presence of different types of childhood abuse.   
For the SDS and the Y-BOCS-du, individual scores were calculated by the researcher based 
on participant response.   
Assistance with data analysis was sought from the Centre of Statistical Consultation 
of the Department of Statistics and Actuarial Sciences at SU.  For objectives one to four (see 
page 16), bivariate analyses were conducted.  For comparisons of sociodemographic 
variables (e.g. age, gender, level of education, etc.), clinical variables (SDS and Y-BOCS-du) 
and CT histories between the two groups (MAUD+ASPD and MAUD-ASPD), cross 
tabulation was used for categorical predictors (e.g. gender, language, employment status), 
with the Fisher exact test, while for ordinal/continuous data (e.g. age, level of education, and 
years of education) one-way analysis of variance (ANOVA) was conducted to compare 
means between the two groups.  The accepted level of significance was < 0.05.  For objective 
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five, a logistic regression was conducted to examine sociodemographic and CT predictors of 
diagnostic group membership, yielding adjusted odds ratios. 
 
3.7  Ethics 
As mentioned earlier, at the time of conducting this study, the overarching study already had 
approval from both the SU Health Research Ethics Committee and the UCT Human Research 
Ethics Committee.  The project was conducted in accordance with the ethical guidelines and 
principles of the international Declaration of Helsinki and the South African Guidelines for 
Good Clinical Practice.  This researcher also received ethics approval from the Department of 
Psychology at UCT on 30 April 2019 (reference number: PSY2019-017).  Ethics, with 
specific reference to informed consent, confidentiality, and risks and benefits, are discussed 
below. 
 
3.8  Informed Consent 
Before the interview started, the participant received a consent form.  The participant was 
instructed to thoroughly read the consent form.  The researcher allowed enough time for the 
reading of the consent form and verbally explained the study procedures in layperson’s terms 
thereafter.  The researcher allowed for and answered any questions that arose.  Only 
participants who provided signed consent were included in the study.  Informed consent 
forms were available in Afrikaans as well as English.  Participation in the study was 
voluntary and participants had the right to withdraw at any stage.  Participants were clearly 
informed about their right to voluntary participation prior to data collection.  The English 





3.9  Anonymity and Confidentiality 
To ensure the anonymity of participants, the researcher assigned a study number to each 
participant (e.g. MA 001).  The participant numbers were kept on a separate database from 
the original identifying information.  Both databases were stored on a password-protected 
computer in a locked office at the SA MRC Unit.  The hard copies of completed 
questionnaires were stored in a file for each participant in a locked drawer in the same office.  
All data were only available to the researcher and his supervisors.  All information that was 
obtained in the study remains confidential and is not discussed outside of the research team.   
 
3.10  Risks and Benefits  
Due to the length of the interview, there was a minimal risk that participants may have felt 
tired by their participation.  Participants were allowed to take breaks during the interview, as 
needed.   
All participants were offered psychological or emotional support or referral for 
treatment of MA dependence and associated problems.  If requested, appropriate referrals 
were made to registered health care facilities/practitioners (e.g. The South African National 
Council on Alcoholism and Drug Dependence (SANCA), Narcotic Anonymous (NA), day 
hospitals with outpatient psychiatric services and/or private practice 
psychologists/psychiatrists).  Participants that experienced emotional distress as result of 
sharing their histories, were offered appropriate referrals to psychologists or counsellors. 
 
3.11  Incentives 
Each participant received a R75 Checkers gift card to compensate for the time spent on the 




CHAPTER  FOUR 
RESULTS 
This chapter presents the results of the study.  It first presents the demographic characteristics 
of each group and the sample as a whole.  It further presents associations of each group with 
illness severity, psychosocial impairment, and childhood trauma (CT).  Lastly, it presents 
findings of a logistic regression of sociodemographic and CT variables in predicting 
comorbid antisocial personality disorder (ASPD) in methamphetamine use disorder (MAUD).  
 
4.1  Demographic Characteristics 
The demographic features of the total sample are depicted in Table 1.  Sixty-two adults with a 
primary diagnosis of MAUD were included in the study.  The sample was predominantly 
female (N = 42; 68%) and aged between 18 and 44 years (M = 30.14 years; SD = 6.64).  The 
majority of participants were of mixed-race ancestry (coloured) (N = 56; 90%), reported their 
first language as a combination of Afrikaans and English (N = 27; 44%), had educational 
attainment between grade eight and 10 (N = 30; 48%) and were unemployed (N = 45; 73%). 
 
Table 1: Demographic features of the total sample 
 N % M Std Dev 
Gender:     
Male 20 32   
Female 42 68   
 
    
Age: - - 30.14 6.14 
 
    
 
Population: 
    
White  2 3   
Black 2 3   
Coloured 56 90   
Other 2 3   
 
    
First Language:     
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Afrikaans 19 31   
English 14 23   
Combined Afrikaans and English 27 44   
African Language 2 3   
 
    
Level of Education:     
Grade 1 - 7 3 5   
Grade 8 - 10 30 48   
Grade 11 - 12 23 37   
College/Technicon 4 6   
University 2 3   
 
    
Years of Education: - - 10.80 2.01 
 
    
Occupation:     
Professional 2 3   
Business owner, business director, 
manager 
2 3   
Homemaker 1 2   
Sales, administrative, clerk, technician 4 6   
Labourer, cleaner 5 8   
Unemployed 45 73   
Other 3 5   
4.2  Associations Between Diagnostic Group and Demographic Variables  
Of the 62 participants, 14 (23%) had MAUD and comorbid ASPD (MAUD+ASPD) whereas 
48 (77%) had MAUD without ASPD (MAUD-ASPD).  Table 2 depicts the demographic 
correlates of MAUD+ASPD and MAUD-ASPD.   
Significant gender differences (df =1) = 8.05; p = <0.01) were found between the two 
diagnostic groups, with the MAUD+ASPD mostly being male (N = 9; 64%), and MAUD-
ASPD mostly female (N = 37; 77%).  No statistically significant differences were found 
between groups in terms of age (F(1, 60) = 0.83; M = 30.15; SD = 6.64; p = 0.37), level of 
education  (F(1, 60) = 0.23; M = 5.55; SD = 0.82; p = 0.50) and number of years of education 
(F(1, 60) = 3.22; M = 10.81; SD = 2.02; p = 0.07).  With regard to employment status, both 




MAUD-ASPD); (p = 1.00).  There was a significant difference between the two diagnostic 
groups with regard to their first language (df = 2) = 7.12; p = 0.03), with patients with English 
as a first language being more common in the MAUD+ASPD group. 
 
Table 2: Comparison of the demographic features of the two diagnostic groups  
  MAUD-ASPD MAUD+ASPD p-value 
Total 48 14  
Percentages % 77 23  
    
Gender:    
Male 11 (23%) 9 (64%) 
<0.01 
Female 37 (77%) 5 (36%) 
    
Age:    
Mean 29.73 31.57  
Std. Dev 6.55 7.01 
    
First Language:    
Afrikaans 17 (37%) 2 (14%) 
<0.01 English 7 (15%) 7 (50%) 
Combined Afrikaans and English 22 (48%) 5 (36%) 
    
Years of Education:    
Mean 10.56 11.64 
0.07 
Std. Dev 2.03 1.78 
    
Occupation:    
Employed  27% 29% 
1.00 
Unemployed  73% 71% 
  
4.3  Association between Diagnostic Group and Illness Severity 
As summarized in Table 3, the total sample presented with moderate illness severity (M = 
23.76; SD = 10.54).  There was no significant difference in levels of illness severity between 









Dev p-value Y-BOCS-du Description  
    
Moderately ill 
MAUD-ASPD 23.71 10.44 
0.90 
MAUD+ASPD 23.93 11.30 
Overall 23.76 10.54  
4.4  Association between Diagnostic Group and Psychosocial Functioning 
As depicted by Table 4, the total sample presented with moderate overall psychosocial 
impairment and disability (M = 17.16; SD = 9.38).  There were no significant differences 
between the two diagnostic groups in the overall SDS score (F(1, 60) = 0.40; M = 17.16; SD 
= 9.38; p = 0.92) or on the specific dimensions of work (F(1, 60) = 0.01; M = 4.82; SD = 
3.45; p = 0.97), social (F(1, 60) = 0.09; M = 5.68; SD = 3.49; p = 0.71) or family (F(1, 60) = 
0.13; M = 6.47; SD = 3.80; p = 0.89) functioning. 
 






Std. Dev SDS Description p-value 
 
     
Work 
0-10 
    
All cases 4.82 3.45 
Moderately impaired 
 
MAUD-ASPD 4.79 3.42 
0.97 
MAUD+ASPD 4.93 3.69 
 
     
Social 
0-10 
    
All cases 5.68 3.49 
Moderately impaired 
 
MAUD-ASPD 5.75 3.53 
0.71 
MAUD+ASPD 5.43 3.44 
 
     
Family 
0-10 
    
All cases 6.47 3.80 
Markedly impaired 
 
MAUD-ASPD 6.56 3.70 
0.89 
MAUD+ASPD 6.14 4.28 
 






    
All cases 17.16 9.38 
Moderately impaired 
 
MAUD-ASPD 17.29 9.31 
0.92 
MAUD+ASPD 16.71 9.96 
4.5  Childhood Trauma  
The differences in rates and severity of exposure to CT between the diagnostic groups are 
depicted in Table 5.  Overall, 98% (N = 61) of the total sample reported a history of CT.  The 
severity of CT reported in the total sample was moderate to severe (M = 56.56; SD = 22.49).  
There was no significant difference in severity of overall Childhood Trauma Questionnaire – 
Short Form (CTQ-SF) scores between the two diagnostic groups (F(1, 60) = 0.72; M = 56.56; 
SD = 22.49; p = 0.30). 
Eighty-seven percent (N = 54) of the sample reported a history of emotional abuse.  
The rates of emotional abuse in the two diagnostic groups did not differ significantly (df =1) 
= 0.03; p = 0.86).  The severity of emotional abuse in the total sample ranged from moderate 
to severe (M = 12.85; SD = 5.69).  There was no significant difference in severity of 
emotional abuse between the diagnostic groups (F(1, 60) = 0.73; M = 12.85; SD = 5.69; p = 
0.43). 
Seventy-three percent (N = 45) of the total sample indicated a history of physical 
abuse.  The rates of physical abuse both diagnostic groups did not differ significantly 
between the diagnostic groups (df =1) = 1.73; p = 0.18).  The severity of physical abuse in the 
total sample was moderate to severe (M = 11.10; SD = 6.20).  There was no significant 
difference between the diagnostic groups in terms of severity of physical abuse (F(1, 60) = 
1.35; M = 11.10; SD = 6.20; p = 0.19).  
With regards to sexual trauma, 56% (N = 35) of the total sample reported a history of 
this type of adversity.  The rate of exposure to sexual abuse did not differ significantly 




sample was moderate to severe (M = 11.15; SD = 7.47).  Severity of sexual abuse were not 
significantly different between the two diagnostic groups (F(1, 60) = 0.006; M = 11.15; SD = 
7.47; p = 0.96). 
Eighty-four percent (N = 52) of the total sample reported a history of emotional 
neglect.  The rate of exposure to emotional neglect did not differ significantly between 
diagnostic groups (df =1) = 1.25; p = 0.26).  The severity of emotional neglect in the total 
sample was low to moderate (M = 11.61; SD = 5.44).  Severity of emotional neglect between 
the two groups was not significantly different (F(1, 60) = 0.59; M = 11.61; SD = 5.45); p = 
0.70). 
Seventy-nine percent (N = 49) of the total sample reported histories of physical 
neglect.  The rate of exposure to physical neglect did not differ significantly between 
diagnostic groups (df =1) = 2.49; p = 0.11).  The severity of physical neglect across the total 
sample was borderline moderate to severe (M = 9.85; SD = 4.23).  Statistical significance was 
reached for differences in physical neglect between the two diagnostic groups (F(1, 60) = 
2.33; M = 9.85; SD = 4.23; p = 0.04), with the MAUD+ASPD group reporting higher levels 
of childhood physical neglect. 
 

















       
Emotional abuse 
5-25 
      
All cases 12.85 5.69 87%  Borderline moderate to severe   
MAUD-ASPD 12.52 5.56 87% 
0.86 
Borderline moderate to severe 
0.43 
MAUD+ASPD 14,00 6.16 85% Moderate to severe  
 
       
Physical abuse 
5-25 
      
All cases 11.1 6.2 73%  Moderate to severe  
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MAUD-ASPD 10.6 6.07 68% 
0.18 
Moderate to severe  
0.19 
MAUD+ASPD 12.79 6.55 85% Borderline severe and extreme 
 
       
Sexual abuse 
5-25 
      
All cases 11.15 7.47 56%  Moderate to severe  
MAUD-ASPD 11.19 7.71 56% 
0.95 
Moderate to severe 
0.96 
MAUD+ASPD 11,00 6.87 57% Moderate to severe 
 
       
Emotional neglect 
5-25 
      
All cases 11.61 5.45 84%  Low to moderate  
MAUD-ASPD 11.52 5.54 81% 
0.26 
Low to moderate 
0.70 
MAUD+ASPD 11.93 5.3 92% Low to moderate 
 
       
Physical neglect 
5-25 
      
All cases 9.85 4.22 79%  Borderline moderate to severe   
MAUD-ASPD 9.42 4.4 75% 
0.11 
Low to moderate 
0.04 
MAUD+ASPD 11.36 3.25 92% Moderate to severe 
 
       




56.56 22.49 98%  Moderate to severe   
MAUD-ASPD 55.25 22.88 -  Moderate to severe  0.30 
MAUD+ASPD 61.07 21.28 - Moderate to severe  
 
4.6  Predicting Group Membership 
The bivariate analyses suggested significant group differences in terms of gender, language, 
and physical neglect, with MAUD+ASPD group members significantly more likely than the 
MAUD-ASPD group to be male, to be English-speaking and to have higher rates of 
childhood physical neglect. 
Standard logistic regression was performed to explore the simultaneous contribution 
of these three variables in predicting group membership.  First, a test of all effects (indicated 
in Table 6) was performed on the variables (i.e. gender, language, and physical neglect) that 
reached statistical significance with bivariate analysis.  Gender (p = 0.01) and language (p = 
0.03) were predictors of diagnostic group.   
As shown in Table 7, odds ratios were then calculated, with the male gender being a 
significant predictor of being diagnosed with comorbid ASPD (beta = 1.08; OR = 8.65; p = 
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0.01).  Male gender increased the probability to be diagnosed with comorbid ASPD more 
than eight times.  Language was also a significant predictor (p = 0.03) of group membership, 
with English as first language increasing the odds more than 11 times to be diagnosed with 
comorbid ASPD (beta = 1.55; OR = 11.38; p = 0.01).  However, severity of physical neglect 
was not a significant predictor of a diagnosis of comorbid ASPD (p = 0.10) when considered 
simultaneously with gender and language.  
Table 6:  Test of all effects for predicting group membership 
  Wald Statistic p-value 
Gender 6.87 0.01 
Language 7.34 0.03 




Table 7: Odds ratios of predictors for MAUD+ASPD 
           
  Odds ratio 
Regression 
coefficient CL lower CL upper p-value 
Gender: Male 8.65 1.08 1.72 43.39 0.01 
Language: 
English 11.38 1.55 1.65 78.61 0.01 
Physical neglect 1.17 0.15 0.97 1.40 0.10 
            
 
4.7  Conclusion 
This chapter presented the results of this study.  Bivariate analyses found that there were 
significant differences between the MAUD+ASPD group and the MAUD-ASPD group in 
terms of gender, language, and histories of severity of physical neglect.  The logistic 
regression showed that MAUD+ASPD were predicted only by male gender and English as a 






The aim of this study was to describe and compare sociodemographic, childhood trauma (CT) 
and clinical severity variables between patients with a primary diagnosis of 
methamphetamine use disorder (MAUD) with and without antisocial personality disorder 
(ASPD) and without ASPD, and to determine the contribution of these variables in predicting 
MAUD+ASPD.  This chapter will discuss the study findings in light of existing literature, 
consider the limitations of the study, and propose some recommendations for future research.  
 
5.1. Rates of Methamphetamine Use Disorder with comorbid Antisocial Personality 
Disorder 
Of the 62 participants that were included in the study, almost a quarter (23%) were diagnosed 
with comorbid ASPD.  Substance use disorders (SUDs) and ASPD often co-occur (Sakai et 
al., 2004) and it has widely been accepted that ASPD has strong associations with stimulant 
use disorders (APA, 2013).  International research in MA-using populations has shown that 
patients often present with antisocial traits, but varying prevalence rates for this dual 
diagnosis have been reported (Cohen et al., 2007; Fletcher & Reback, 2013).  .  In this study 
MAUD+ASPD was markedly lower than what was found in international works by Lecomte 
et al. (2010) who reported rates of 68% and Fletcher and Reback (2013) who found 
prevalence rates of 34%.  The high rates found in these studies may be accounted for by the 
sampling methods used.  Lecomte and colleagues sampled patients from emergency rooms at 
local hospitals, who presented with MA psychosis and who were homeless.  The authors 
highlighted that ASPD was prevalent among patients with severe mental illness (such as 
schizophrenia/psychosis) and individuals with housing instability (Lecomte et al., 2010).  
Similar to Lecomte et al. (2010), Fletcher and Reback (2013) sampled only male participants 
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who were homeless and did not seek treatment for MA abuse.  The lower rates found in our 
study might be accounted for by the predominance of female participants in this sample. 
As discussed in Chapter 2, there are a number of possible reasons for the high 
prevalence of ASPD in MAUD.  Chronic use of MA often leads to long-lasting neurological 
changes that may result in psychiatric problems even after use has stopped (Aronson, 2016) 
and a dual diagnosis of MAUD+ASPD can be accounted for by diagnostic similarity of both 
disorders.  In general, SUDs and ASPD share common underlying diagnostic features (Brook 
et al., 2016; Dellazizzo et al., 2018; Rzhetsky et al., 2007; Smith et al., 2014; Trull et al., 
2000).  These may include genetic, behavioural or cognitive factors (Rzhetsky et al., 2007; 
Smith et al., 2014) which accompany antisocial behaviours, such as criminality and violence 
(Cohen et al., 2007) and are often implicated in a diagnosis of ASPD and seen in MAUD 
(APA, 2013). 
In conclusion, this study found that a substantial minority of the sample has 
MAUD+ASPD, although the rate was lower than has been reported in previous international 
studies.  However, this finding should be interpreted as preliminary as the sample size was 
small and the use of larger and more representative South African cohorts may yield a 
different prevalence rate.    
 
5.2  Demographic Features of the Sample 
The majority (93%) of participants from this study were of mixed-ancestry.  The high rates of 
participants that were of mixed ancestry may be accounted for by the catchment areas of the 
referral sites (e.g. non-governmental organizations that specifically provide services to people 
with substance use disorders who can not afford private healthcare fees) and location of such 
referral sites, treatment-seeking patterns, and there may be several other reasons related to the 
sampling procedures for this study.  Further, ethnicity was not associated with 
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MAUD+ASPD and did not pose an increased risk for the relevant dual comorbidity in this 
sample.   
International research on gender and MA use has revealed mixed results (e.g. Cohen, 
Greenberg, Uri, Halpin, & Zweben, 2007; Simpson et al., 2016).  However, local research 
indicates that the majority of patients who use MA are male (e.g. Watt et al., 2014).  In 
contrast, in this South African study, the majority of participants were female.  This 
discrepancy could be explained by our recruitment strategy, i.e. interviewing a large cohort of 
patients from an inpatient-treatment-centre that provided care only for females with substance 
use and associated problems.  
The mean age of the participants in this sample was 30 years and was slightly higher 
than what has been found in other South African studies (Akindipe et al., 2014).  In line with 
other research, it appears that  MA use and MAUD are common among younger individuals 
(e.g. Akindipe et al., 2014).  The finding that  almost half the sample in the current study 
were persons with lower levels of education (48% of participants only had an educational 
level between grades eight to 10 and only nine percent of the sample had education further 
than high school) may again reflect the sampling bias of the study (recruiting mainly from 
state services and non-governmental organizations), but is in line with much previous 
international and local research that indicates lower educational attainment among 
populations with MUAD (e.g. Akindipe et al., 2014; Cservenka & Ray, 2017; Harker et al., 
2008; Lecompte et al., 2010; Meade et al., 2012; Polcin et al., 2012; Semple et al., 2005; 
Watt et al., 2014).  By contrast, Eslami-Shahrbabaki et al. (2015) reported a higher level of 
education an Iranian sample of psychiatric patients diagnosed and hospitalized for MA-
psychosis, where the majority had education on diploma level.  One local study highlighted 
that MA use often led to school dropout (Watt et al., 2014).  However, it must be highlighted 
that the current study did not investigate at which stage/level of schooling MA use was 
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initiated.  Thus, we can not infer that MA use lead to lower levels of educational attainment 
in this sample. 
A large majority of the patients (almost three quarters) were unemployed.  South 
Africa is known to have one of the highest levels of unemployment in the world (Burger & 
Fourie, 2019) and our finding may simply reflect the high levels of unemployment in the 
country.  However, considering the psychosocial impact of stimulants (APA, 2013) such as 
MA, it is also possible that users may have difficulty to successfully obtain or maintain 
employment.  One of the hallmarks of MAUD is a failure to fulfil major role obligations at 
work which, perhaps, in some cases, may have lead to dismissal of employment (APA, 
2013).  Methamphetamine use may often interfere and limit future career prospects (Watt et 
al., 2014).  Furthermore, South African laws on substance use and the work place may also be 
a contributing factor that impacts unemployment in this sample.  South African labour law 
implemented processes that ultimately can lead to dismissal of employees that test positive on 
routine drug tests at work (The South African Labour Guide, 2019).  As the sample was 
predominantly female, it might also explain the general high rates of unemployment, as 
previous works have found that women who use MA are often unemployed or 
underemployed (Cohen et al., 2007).  It is also possible that the high level of unemployment 
in the sample reflects the referral sources from which the participants were drawn as most 
referrals were from government rather than private settings. 
 
5.3  Demographic Factors Associated with Comorbid Antisocial Personality Disorder   
The study found that there were few significant sociodemographic differences between the 
two diagnostic groups.  An expected finding was the significant difference in gender between 
the two diagnostic groups.  The MAUD+ASPD group was predominantly male and the 
MAUD-ASPD group predominantly female.  The MAUD+ASPD group had almost double 
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the number of males (N = 9) compared to females (N = 5).  The link between ASPD and male 
gender has repeatedly been reported in the literature (e.g. Yang & Coid, 2007) and the 
predominance of males in the ASPD group is moreover consistent with recent findings  that 
men who use MA are more likely to present as antisocial compared to women who use MA 
(Chun et al., 2017; Polcin et al., 2012).  Other authors have suggested that ASPD may be 
underdiagnosed in females, due to the emphasis on aggressive items in the definition of 
conduct disorder, for which traits have to be prominent since childhood to be able to make a 
diagnosis of ASPD (APA, 2013).  The sex-paradox or group resistance hypothesis suggests 
that females may have a higher etiological threshold for the development of ASPD as females 
are often raised with a gender-role that minimizes acts of violence (Yang & Coid, 2007).  
Additionally, other research on gender in ASPD has implicated neurological factors to 
account for the increased prevalence among males (Raine et al., 2011).  This may also 
account for the predominance of males in the MAUD+ASPD group.   
There was a significant difference between the two diagnostic groups with regards to 
language, with English-only speakers being significantly more prevalent in the 
MAUD+ASPD group.  This finding should, however, be interpreted with caution as it might 
not hold an accurate reflection of the participant’s proficiency in home language or mother 
tongue.  Many of these participants may have come from homes that spoke Afrikaans only or 
both Afrikaans and English, but for reasons that were not explored further chose to indicate 
English as their mother tongue in the interview. 
No difference was found between the two diagnostic groups with regard to age, 
ethinicity, or education.  The findings on age and ethnicity were not unexpected, as the study-
sample had a relatively narrow age range (18-44 years) and a large majority (90%) of patients 
were of mixed-ancestry.   
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The unemployment rates in both groups were similarly high.  Thus, the study suggests 
that a comorbid diagnosis of ASPD does not result in an increased risk to be unemployed, 
probably because the comorbid diagnosis of ASPD was not associated with greater illness 
severity and psychosocial disability.  Overall, other than male gender and English as first 
language, sociodemographic factors were not significantly correlated with the MAUD+ASPD 
dual diagnosis, suggesting that other factors may better account for the presence of this 
comorbidity in the current sample. 
 
5.4  Association of Childhood Trauma with Methamphetamine Use Disorder  
In line with other works, this study showed that, in general, exposure to childhood trauma in 
the MAUD population is high.  Ninety-eight percent of the participants in this study reported 
a history of exposure to CT.  This rate is notably higher when compared to local research by 
Slopen et al. (2010) who found that only 41% of their adult participants from the general 
South African population reported a history of childhood adversity.  It was also markedly 
higher than the rates of 50% reported in a study by Ding and colleagues  (2014) who 
investigated CT in patients with a history of MA use.  In the current sample, the highest rates 
of adversity were reported for emotional abuse (87%) and emotional neglect (84%).  These 
are notably higher than what has been reported in general population studies of both 
adolescents (Ward, Artz, Leoschut, Kassanjee, & Burton, 2018, 2018) and adults (Machisa et 
al., 2016) in South Africa.   It was also almost double the rate found in international works 
that investigated emotional adversity in MA using patients (Ding et al., 2014). Similarly, high 
rates were reported in terms of exposure to physical abuse (73%) and physical neglect (79%).  
Physical abuse was also greatly higher than what has been reported in retrospective studies 
done with nationally representative samples of adolescents (18%; Ward et al, 2018)  and 
adults (a rate of 19% was reported in the South African Stress and Health Study) (Kaminer et 
57 
 
al., 2008; Slopen et al., 2010).  Sexual abuse, although high (56%), was lower compared to 
the other forms of abuse in the total MAUD sample.  It was notably higher than what has 
been reported in other local research that explored childhood sexual abuse in MA using  
(Berg et al., 2017) and general populations (12%; Ward et al., 2018).  Some authors have 
suggested that disclosure of sexually related trauma or abuse is more likely in research using 
confidential and self-completed questionnaires (Ward et al., 2018).  The CTQ-SF was a self-
report questionnaire and perhaps this may account for the high rates that were found in this 
study.  
In general, the findings of the current study suggest that histories of childhood trauma 
may be particularly prevalent in South Africans with MAUD compared to the general South 
African population.  The severity of overall CT reported in the sample was moderate to 
severe.  Moderate to severe levels were reported for physical abuse, sexual abuse and 
physical neglect.  Emotional abuse reached borderline scores of moderate to severe levels.  
Emotional neglect also had lower levels compared to the other abuse and was only low to 
moderate.  Overall, the severity of CT and the specific forms thereof were higher that what 
has been reported in a multinational (including South Africa) study that included community 
and clinical participants (MacDonald et al., 2016).  Additionally, the mean scores of the 
severity of overall CT and specific forms thereof were greater in our study than what has 
been reported in previous international samples of substance-using participants (Bernstein et 
al., 2002).  Thus, the findings from our study suggest that this sample may have had both 
greater exposure and more severe histories of overall CT and of specific forms of childhood 
trauma than what has been found in other works.  Some studies  have shown that, in general, 
people with substance use disorders are likely to have significant histories and higher rates of 
CT (Ekinci & Kandemir, 2015) compared to non-using populations (Bernstein et al., 2003; 
Hogarth et al., 2019).  It has been suggested that women, compared to men, report the most 
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extensive histories of childhood abuse in MAUD populations (Messina et al., 2008).  The 
predominance of females in this sample may account for the high rates of trauma reported. 
It has been suggested that a better understanding of the association of CT between 
SUDs and psychiatric comorbidity may inform treatment intervention strategies and medical 
treatment programs  to enhance positive health outcomes for users who are living with 
psychological consequences of childhood abuse (Lopez-Patton et al., 2016).  Our findings 
emphasise that there is a need for further research, with larger and more gender-balanced 
local-samples, to explore and recognise the prominence of CT histories in populations with 
MAUD and factor this into treatment approaches. 
 
5.4.1  Childhood Trauma and Group Membership 
This study explored differences in CT between the diagnostic groups.  Literature suggests 
that people with MAUD with a history of CT have increased risk to have a comorbid 
diagnosis of ASPD (Lecomte et al., 2010) and Messina et al. (2008) found that populations 
who use MA and who have a diagnosis of ASPD report greater experiences of childhood 
abuse compared to those without ASPD.  However, this study found no significant 
differences in rates of exposure to overall CT, physical abuse and neglect, sexual abuse, and 
emotional abuse between the MAUD+ASPD and MAUD-ASPD groups.   
Similarly, there was no difference between the diagnostic groups in overall severity of 
CT, with both diagnostic groups reporting moderate to severe overall histories.  Further, this 
study found no diagnostic group differences in severity of CT for emotional abuse and 
neglect, physical abuse, or sexual abuse between the two diagnostic groups.  However, 
statistical significance was reached in differences between the two diagnostic groups for the 
severity of physical neglect.  The MAUD+ASPD group reported higher levels of childhood 
physical neglect.  Some works have highlighted associations between physical maltreatment 
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and both MAUD (Lopez-Patton et al., 2016) and ASPD (Sher et al., 2015).  While bivariate 
analyses in the current study suggest that (increased) severity of physical neglect was 
associated with a comorbid diagnosis of ASPD in this sample, this relationship was not 
sustained when physical neglect was considered simultaneously with other variables in a 
regression analysis. In the bivariate analysis, physical neglect may therefore have been a 
proxy for one of the other variables that were later included in the regression analysis, such as 
gender.  
Overall, this study found no significant association between CT exposure or severity 
and comorbid ASPD in participants with MAUD, suggesting that other unexplored factors 
may account for the MAUD+ASPD comorbidity in this sample. 
 
5.5  Illness Severity and Psychosocial Disability  
Another objective of this study was to compare illness severity and psychosocial disability 
between MAUD+ASPD and MAUD-ASPD.  This study found that the overall sample 
described their illness severity as mild and with moderate psychosocial impairment.  A 
noteworthy finding was that the patients in this sample presented with lower illness severity 
compared to other works that used similar measures to investigate illness severity in people 
with MAUD (Grant et al., 2010).  This was an unexpected finding, as research has 
demonstrated that individuals with lower levels of education, like that found in our sample, 
may be at more risk for increased negative sequela associated with MA use (Eslami-
Shahrbabaki et al., 2015).  Additionally, there was no difference in illness severity of MA use 
between the diagnostic groups.  Our findings were consistent with other works that also 
found no significant difference in illness severity between patients with MA use only and 
patients with MA use and psychiatric comorbidities (Eslami-Shahrbabaki et al., 2015). 
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It has been widely accepted that MA use affects global functioning (APA, 2013).  A 
recent South African study (Lanesman et al., 2019) showed that individuals with MAUD 
experience problems on various levels of functioning.  Lanesman and colleagues (2019) 
suggested that individuals with MAUD report negative effects on social, work and family 
functioning at an interpersonal, intrapersonal, and community level (Lanesman et al., 2019).   
Overall, the patients in this study presented with moderate impairment and disability. 
However, overall psychosocial functioning did not differ between the MAUD+ASPD and 
MAUD-ASPD groups and there were also no differences in specific domains of functioning 
(work, family, and social).  These findings were unexpected as ASPD has often been 
associated with problems that can have a negative impact on family, social, occupational, and 
global functioning (APA, 2013).  For example, individuals with ASPD often present with 
irritability, aggressiveness, and impulsivity (APA, 2013) which may negatively affect 
relationships with family members, in social situations, or with co-workers.  Other hallmarks 
of ASPD are being deceitful, lying, using aliases, or conning others for self profit or pleasure 
(APA, 2013) and are traits that arguably may lead to impairment on multiple levels of 
functioning. 
An explanation that may account for the lower levels of illness severity and 
psychosocial impairment reported here is the fact that most participants of this study were 
recruited from an inpatient treatment centre, where they have received treatment that may 
have resulted in reduced illness severity and improved psychosocial functioning already. 
 
5.6  Predicting Comorbid Antisocial Personality Disorder in Methamphetamine Use 
Disorder 
The final objective of this study was to determine whether MAUD+ASPD can be predicted 
by sociodemographic variables and different types and or severity of CT when these are 
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considered simultaneously. Lawrie and colleauges (2019) suggest that it may be vital to 
identify risk factors in patients as it could be used to inform patients, carers, and health 
professionals about how to improve prevention or treatment of psychiatric disorder (Lawrie et 
al., 2019).   
The regression analysis included only those variables found to be significantly 
associated with MAUD+ASPD in bivariate analyses: gender, language and severity of 
physical neglect. It must be noted that logistic regression analysis with small samples, such as 
this study, need to be interpreted with caution as they may result in an overestimation of the 
odd’s ratios.  In the regression analysis, language was a predictor for comorbid ASPD, with 
English-only-speakers having 11 times greater odds of being in the MAUD+ASPD group.  
Although this may be an interesting finding, we are of the opinion that this should be 
interpreted with caution.  It must be emphasized that the study mainly consisted of three 
language groups and had a relatively small sample size and, further, professed first language 
at the interview may not always be participants’ actual home language.  Disseminating 
possibly false-positive results may potentially hold deleterious consequences related to 
prejudice and discrimination in this population (Lawrie et al., 2019).  Further exploration in 
future research is needed for optimal and reliable prediction and to rule out a false-positive 
result.  Additionally, further research is warranted on the role of language as a predictor of 
MAUD+ASPD as preferred language may be a proxy for other factors linked to ethnicity and 
class in South Africa. 
Another predictor of dual MAUD+ASPD diagnosis was male gender.  Being male 
increased the odds of a comorbid diagnosis of ASPD more than eight times compared to 
females.  This finding was not unexpected, as ample research supports the link between 
ASPD and the male gender (APA, 2013; Chun et al., 2017; Holzer & Vaughn, 2017; Loots & 
Louw, 2012; Salyer, 2007).  However, during the investigation with bivariate tests it was 
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found that almost a quarter (23%) of the MAUD-ASPD was male, indicating that not all men 
with MAUD will have comorbid ASPD.  Lawrie and colleagues (2019) emphasize that 
diagnostic tests normally generate binary outcomes (disease present or absent) and there may 
be a need for further investigation that will promote individualized predictions (Lawrie et al., 
2019) and the identification of specific risk factors for ASPD in males with a primary 
diagnosis of MAUD. 
Moreover, the findings from the logistic regression suggested risk factors that are 
historically determined and “fixed” (i.e. male gender and English as first language).  It is not 
possible to say which diagnosis (MAUD or ASPD) preceded the other.  Nevertheless, 
comorbid ASPD has been associated with reduced prosocial or health-related behaviours 
(Fletcher & Reback, 2013), such as less treatment-seeking efforts (Lin et al., 2004), and/or 
increased psychiatric and physiological sequela (APA, 2013; Callaghan, Cunningham, Sykes, 
& Kish, 2012; Meredith et al., 2005).  Patients with MAUD+ASPD are also more likely to 
relapse to heavy MA use after treatment (Fridell et al., 2006) and it has been suggested that 
specialized treatment is needed for patients with a comorbid diagnosis of ASPD (Fletcher & 
Reback, 2013).  Identifying male gender as a significant predictor of MAUD+ASPD in a 
South African sample suggests that screening of male MAUD patients for ASPD may be 
indicated during treatment intake. This may ultimately facilitate the selection and the 
development of prevention and treatment plans to address ASPD comorbidity in MAUD and 
thus improve outcomes.   
 
5.7  Limitations and Recommendations 
This study had several limitations. First, this research project was based on a cross-sectional 
study design which is particularly suitable for estimating the prevalence of a behaviour or 
disease in a population (Sedgwick, 2014) and cannot draw firm conclusions about causality 
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of MAUD and ASPD.  Second, it has been recommended that findings in small samples such 
as that in the current study should only be interpreted as preliminary (Lanesman et al., 2019).  
The study may have been under-powered to detect significant other differences in 
sociodemographic variables, CT histories, severity and impairment between the diagnostic 
groups. Third, together with the small sample size, the use of a clinician-referred, treatment-
seeking, volunteer sample also limits the generalizability of the findings to MA dependent 
individuals within the general (non-treatment seeking) population.  Most of the participants 
of the study were recruited from drug treatment centres, psychiatric institutions, and other 
health care practitioners.  Moreover, as previously mentioned, polysubstance use is rife 
within populations with MAUD and the findings should also be interpreted with caution as no 
analysis examined the role of polysubstance in this sample.  Finally, this study did not collect 
data on treatment response in the two groups. This would have yielded valuable information 
about whether MAUD+ASPD predicts treatment drop-out and treatment outcome in this 
South African sample, as it has been shown in international studies (Öhlin et al., 2011).    
Future research should use larger and more representative samples that, for example, 
include a broader range of age, ethnic groups, languages, and educational histories, to explore 
the risk factors and outcomes associated with comorbid ASPD or other personality disorder 
in MAUD. Such research may hold valuable implications in prevention, treatment, and 
maintenance of MAUD and MAUD+ASPD.  A better understanding of demographic and 
other risk factors, and of clinical features, may potentially guide the selection of treatment 
targets, harm reduction strategies, and relapse prevention in MAUD. 
 
5.8  Conclusion 
This study examined factors associated with a comorbid diagnosis of ASPD in a treatment- 
seeking sample of participants with MAUD. Although the presence of comorbid ASPD 
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(23%) was lower in this sample than in some previous studies, this rate is higher than would 
be expected in a predominantly female sample and highlights the need for a better 
understanding of this dual diagnosis.  Gender and language differed significantly between the 
MAUD+ASPD and MAUD-ASPD group, with those in the MAUD+ASPD group more 
likely to be male and having English as a first language.  Men who use MA are thus more 
prone to antisocial behaviour, which complicates their substance use condition. Lack of 
motivation, disruptiveness, impulsivity, and general disregard for others, typical of ASPD, 
may all contribute to lower rates of engagement, retention, and poorer outcomes for 
individuals undergoing substance abuse treatment, and thus present increased challenges to 
the treatment setting.  The language finding should be treated with some caution and warrants 
further investigation.  Other sociodemographic factors and most aspects of CT history were 
not associated with MAUD+ASPD in this sample.  Severity of physical neglect, while 
associated with diagnostic group in bivariate analysis, did not maintain significance when 
considered with gender and language in a regression analysis.  Finally, there was no 
difference in levels of clinical severity of MAUD or psychosocial impairment between the 
two diagnostic groups. Given the use of a small, treatment-seeking sample, future research 
using larger, more representative samples may allow for more robust investigation of the 
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Appendix A - Demographics Questionnaire 
 





Full names:   Surname:    
 
Sex:   1 – male, 2 – female  Interviewer: 
 
Date of Birth:    1 – Christine 
Participant’s Age:   2 – Other 
Contact Details :  
Phone (H):    Phone (W): 
   
Cell:   e-mail: 
  








Population: Language (mother tongue):    
1  –  White SA, Afrikaans speaking 1 – Afrikaans                                               
2  –  White SA, mixed Afrikaans and English 2 – Mixed Afrikaans and English                           
3  –  White SA, English-speaking 3 – English  
4  –  Coloured   4 – African Language    
5  –  Malaysian   5 – Other Language (German, etc.) 
                                                                          
85 
 
6  –  Black   6 – Mixed Afrikaans and other    
                                                                                 
7  –  Indian  
8  –  Persons from other Asian decent 
9  –  Jewish     
10 –Other: ____________________________________ 
  
Highest Level of Education (completed): Occupation: 
  
1 – No School 1 – Professional 
2 – Grade 1-7 2 – Business Owner, Business Director / 
Manager 
3 – Grade 8-10 3 – Homemaker 
4 – Grade 11-12 4 – Sales, Admin, Clerical, Technician 
5 – College / Technicon 5 – Laborer / Cleaner 
6 – University  6 – Student 
 7 – Artist / Musician / Writer 
 8 – Pensioner 
 9 – Disability Pensioner 
 10 – Unemployed 
 11 – Other: ________________________ 
Health: 




2. What is the date of your last doctor’s (GP) visit? 
  







4. Do you have any metal prosthesis (e.g. pacemaker or metal clips)? 
  





Diagnosis – Current Diagnosis – Past  
  Onset:       Onset:    End: 
  
  Onset:       Onset:    End: 
  
  Onset:       Onset:    End: 
  


























*PAST-12-MONTH NON-ALCOHOL SUBSTANCE USE DISORDER* 
 
REVIEW HISTORY OF DRUG USE ON PAGES 7-8 OF PATIENT OVERVIEW (OR PAGES 5-6 OF NON-PATIENT OVERVIEW). IF 
DENIES ANY LIFETIME DRUG USE IN OVERVIEW, CHECK HERE  AND GO TO NEXT MODULE. 
FOR DRUGS USED IN PAST 12 MONTHS: CODE “3” FOR EACH DRUG CLASS BELOW BASED ON CODING IN RIGHT HAND COLUMN 
OF OVERVIEW DRUG ASSESSMENT (PATIENT OVERVIEW PAGES 7-8 OR NON-PATIENT OVERVIEW PAGES 5-6). OTHERWISE, 



















3 3 3 3 3 3 3 3 
1 1 1 1 1 1 1 1 
E39 E40 E41 E42 E43 E44 E45 E46 
 
IF ALL DRUG CLASSES CODED “1” FOR PERIOD OF PAST 12 MONTHS, CHECK HERE  AND GO TO *PRIOR-TO-PAST-12- 
MONTH NON-ALCOHOL SUBSTANCE USE DISORDER* E.26. 
 
FOR ALL CLASSES CODED “3” ABOVE, CIRCLE THE APPROPRIATE COLUMN HEADERS (DRUG CLASS NAMES) ON PAGES E.11 TO 
E.18, BASED ON ONE OF THE FOLLOWING OPTIONS: (Indicate option used with a check mark in front of option) 
 
  OPTION #1: DETERMINE THE PRESENCE OF SUBSTANCE USE DISORDER IN PAST 12 MONTHS (SINGLE MOST 
PROBLEMATIC SUBSTANCE). 
 
Which drug or medication caused you the most problems over the past 12 months, since (1 YEAR AGO)? 
Which one did you use the most? (Which was your “drug of choice?”) 
 
START WITH THE DRUG CLASS THAT WAS MOST PROBLEMATIC OR USED THE MOST. RETURN HERE IF CRITERIA ARE 
NOT MET FOR INITIAL DRUG CLASS AND THERE IS ALSO EVIDENCE OF CLINICALLY SIGNIFICANT USE OF OTHER DRUG 
CLASSES. ASK ABOUT EACH DRUG CLASS IN SEQUENCE UNTIL EITHER THE CRITERIA ARE MET FOR A SUBSTANCE 
USE DISORDER IN THE PAST 12 MONTHS OR ELSE NONE OF THE DRUG CLASSES MEET CRTERIA. 
 
  OPTION #2: DETERMINE PRESENCE OF THE THREE SUBSTANCE CLASSES MOST HEAVILY USED OR MOST 
PROBLEMATIC IN THE PAST 12 MONTHS. 
 
Which drugs or medications caused you the most problems over the past 12 months, since (1 YEAR AGO)? 
Which ones did you use the most? (Which were your “drugs of choice?”) 
 
  OPTION #3: DETERMINE PRESENCE OF SUBSTANCE USE DISORDER IN THE PAST 12 MONTHS FOR ALL DRUG 






















































   
 
 NON-ALCOHOL SUBSTANCE USE DISORDER CRITERIA 
Now I’d like to ask you some more questions 
about your use of (DRUG CLASS[ES] CIRCLED 
IN COLUMN HEADERS) in the past 12 months, 
since (1 YEAR AGO). 
 
FOR EACH CRITERION, ASK QUESTIONS FOR 
CIRCLED DRUG CLASS(ES) ONLY: 
A. A problematic pattern of substance use leading to clinically significant 
impairment or distress, as manifested by at least two of the following 
occurring within a 12-month period: 
During the past year, have you found that 
once you started using (DRUG) you ended up 
using much more than you intended to? For 
example, you planned to have (SMALL 
AMOUNT OF DRUG) but you ended up having 
much more. (Tell me about that. How often 
did that happen?) 
IF NO: What about using (DRUG) for a 
much longer period of time than 
you were intending to? 
1. The substance is often taken in larger amounts OR over a longer period 


















3 3 3 3 3 3 3 3 
2 2 2 2 2 2 2 2 
1 1 1 1 1 1 1 1 
? ? ? ? ? ? ? ? 
E51 E52 E53 E54 E55 E56 E57 E58 
 
 
During the past year, have you wanted to 
stop or cut down using (DRUG), or control 
your use of (DRUG)? 
IF YES: How long did this desire to stop, 
cut down, or control your use of (DRUG) 
last? 
IF NO: During the past year, did you ever 
try to cut down, stop, or control your 
use of (DRUG)? How successful were 
you? (Did you make more than one 
attempt to stop, cut down, or control 
your use of [DRUG]?) 
2. There is a persistent desire OR unsuccessful efforts to cut down or 


















3 3 3 3 3 3 3 3 
2 2 2 2 2 2 2 2 
1 1 1 1 1 1 1 1 
? ? ? ? ? ? ? ? 
















During the past year, have you spent a lot of 
time getting (DRUG) or using (DRUG) or has it 
taken a lot of time for you to get over the 
effects of (DRUG)? (How much time?) 
3. A great deal of time is spent in activities necessary to obtain the substance, 


















3 3 3 3 3 3 3 3 
2 2 2 2 2 2 2 2 
1 1 1 1 1 1 1 1 
? ? ? ? ? ? ? ? 
E67 E68 E69 E70 E71 E72 E73 E74 
 
 
Have you had a strong desire or urge to use 
(DRUG) in between those times when you 
were using (DRUG)? (Has there been a time 
when you had such strong urges to use 
(DRUG) that you had trouble thinking about 
anything else?) 
IF NO: How about having a strong desire 
or urge to use (DRUG) when you were 
around people with whom you used 
(DRUG)? 


















3 3 3 3 3 3 3 3 
2 2 2 2 2 2 2 2 
1 1 1 1 1 1 1 1 
? ? ? ? ? ? ? ? 
E75 E76 E77 E78 E79 E80 E81 E82 
 
During the past year, have you missed work 
or school or often arrived late because you 
were intoxicated, high, or recovering from 
the night before? 
IF NO: How about doing a bad job at work 
or school, or failing courses or flunking 
out of school because of your use of 
(DRUG)? 
IF NO: How about getting into trouble 
at work or school because of your use 
of (DRUG)? 
IF NO: How about not taking care 
of things at home because of your 
use of (DRUG), like making sure 
there is food and clean clothes for 
your family and making sure your 
children go to school and get 
medical care? How about not 
paying your bills? 
IF YES TO ANY: How often? 
5. Recurrent substance use resulting in a failure to fulfill major role obligations at 
work, school, or home [(e.g., repeated absences or poor work performance 
related to substance use; substance-related absences, suspensions, or 


















3 3 3 3 3 3 3 3 
2 2 2 2 2 2 2 2 









? ? ? ? ? ? ? ? 
E83 E84 E85 E86 E87 E88 E89 E90 
 
IF NOT ALREADY KNOWN: During the past year, 
has your use of (DRUG) caused problems with 
other people, such as with family members, 
friends, or people at work? (Have you found 
yourself regularly getting into arguments 
about your [DRUG] use? Have you gotten into 
physical fights when you were taking [DRUG]?) 
IF YES: Have you kept on using (DRUG) 
anyway? 
6. Continued substance use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of the 
substance [(e.g., arguments with spouse about consequences of 


















3 3 3 3 3 3 3 3 
2 2 2 2 2 2 2 2 
1 1 1 1 1 1 1 1 
? ? ? ? ? ? ? ? 
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Have you had to give up or reduce the time 
you spent at work or school, with family or 
friends, or on your hobbies because you 
were using (DRUG) instead? 
7. Important social, occupational, or recreational activities given up or reduced 


















3 3 3 3 3 3 3 3 
2 2 2 2 2 2 2 2 
1 1 1 1 1 1 1 1 
? ? ? ? ? ? ? ? 

















Has your use of (DRUG) during the past year 
caused you any problems like making you very 
depressed, irritable, anxious, paranoid, or 
extremely agitated? What about triggering 
panic attacks, making it difficult for you to fall 
or stay asleep, putting you into a “mental fog,” 
or making it so you couldn’t recall what 
happened while you were using (DRUG)? 
 
Has your use of (DRUG) caused physical 
problems, like heart palpitations, coughing or 
trouble breathing, constipation, or skin 
infections? 
 
IF YES TO EITHER OF ABOVE: Have you kept on 
using (DRUG) anyway? 
9. Substance use is continued despite knowledge of having a persistent or 
recurrent physical or psychological problem that is likely to have been 
caused or exacerbated by the substance [(e.g., recurrent cocaine use 


















3 3 3 3 3 3 3 3 
2 2 2 2 2 2 2 2 
1 1 1 1 1 1 1 1 
? ? ? ? ? ? ? ? 




Have you found that you needed to use much 
more (DRUG) in order to get the feeling you 
wanted than when you first started using it? 
IF YES: How much more? 
 
IF NO: What about finding that when you 
used the same amount, it had much less 
effect than before? 
 
IF PRESCRIBED MEDICATION: Were you taking 
(DRUG) exactly as your doctor told you to? (Did 
you ever take more of it than was prescribed or 
run out of your prescription early? Did you ever 
go to more than one doctor in order to get the 
amount of medication you wanted?) 
10. Tolerance, as defined by either of the following: 
 
a. A need for markedly increased amounts of the substance to achieve 
intoxication or desired effect. 
 
b. Markedly diminished effect with continued use of the same amount of 
the substance. 
 
Note: If opioids, sedative/hypnotic/anxiolytic medications, or stimulant 
medications are taken solely under appropriate medical supervision, this 


















3 3 3 3 3 3 3 3 
2 2 2 2 2 2 2 2 
1 1 1 1 1 1 1 1 
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THE FOLLOWING ITEM DOES NOT APPLY TO 
INHALANTS, PCP, OR HALLUCINOGENS. 
 
During the past year, have you had any 
withdrawal symptoms, in other words felt sick 
when you cut down or stopped using (DRUG)? 
IF YES: What symptoms did you have? 
REFER TO LIST OF WITHDRAWAL SYMPTOMS 
ON E.28. 
IF NO: After not using (DRUG) for a few 
hours or more, did you sometimes use it 
or something like it to keep yourself from 




11. Withdrawal, as manifested by either of the following: 
 
a. The characteristic withdrawal syndrome for the substance (see page 
E.28). 
 
b. The same (or a closely related) substance is taken to relieve or avoid 
withdrawal symptoms 
 
Note: This criterion does not apply to inhalants, PCP, or hallucinogens. 
Note: If opioids, sedatives/hypnotics/anxiolytics medications, or 
stimulant medications are taken solely under appropriate medical 












3 3 3 3 3 
2 2 2 2 2 
1 1 1 1 1 
? ? ? ? ? 




















PAST-12-MONTH NON-ALCOHOL SUBSTANCE USE DISORDER CODING 
  
SEDATIVE/ 




HALLUCIN-  OTHER/ 
OGENS UNKNOWN 
AT LEAST TWO SUBSTANCE 
USE DISORDER ITEMS 
CODED “3” FOR THE PAST 
12 MONTHS 
 
3 3 3 3 3 3 
1 1 1 1 1 1 







1 – Mild: 2-3 sxs. 1=mild 1=mild 1=mild 1=mild 1=mild 1=mild 1=mild 1=mil 
2 – Moderate: 4-5 sxs. 2=mod 2=mod 2=mod 2=mod 2=mod 2=mod 2=mod 2=mo 
3 – Severe: 6+ sxs. 3=sev 3=sev 3=sev 3=sev 3=sev 3=sev 3=sev 3=sev 
 E137 E139 E141 E143 E145 E147 E149 E151 
 
IF SELECTED OPTION #1 (MOST PROBLEMATIC SUBSTANCE): 
 
IF THERE IS EVIDENCE OF CLINICALLY SIGNIFICANT USE OF ANOTHER DRUG CLASS IN PAST 12 MONTHS (OTHER THAN 
THOSE ALREADY ASSESSED), GO BACK TO E.11 AND RE-ASSESS CRITERIA FOR THAT DRUG CLASS. OTHERWISE, GO TO 
*PRIOR-TO-PAST-12-MONTH NON-ALCOHOL SUBSTANCE USE DISORDER* E.26. 
 
IF SELECTED OPTION #2 (THREE MOST HEAVILY USED) OR OPTION #3 (ALL DRUG CLASSES AT USE THRESHOLD): 
 
IF NO DRUG CLASSES CODED “3” (I.E., NO CURRENT [PAST YEAR] SUBSTANCE USE DISORDER), GO TO *PRIOR-TO- 
PAST-12-MONTH NON-ALCOHOL SUBSTANCE USE DISORDER* E.26. 
 
 
INDICATE SPECIFIC NAME(S) OF 
SUBSTANCE(S) FOR WHICH CRITERIA 
WERE MET (I.E., CODED “3” ABOVE): 
 


























   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
























































SCID-RV (for DSM-5®) (Version 1.0.0) List of Withdrawal Symptoms Substance Use Disorders E.28 
 
LIST OF WITHDRAWAL SYMPTOMS (FROM DSM-5 CRITERIA) 
 
Listed below are the characteristic withdrawal syndromes for those classes of psychoactive substances for which a withdrawal 
syndrome has been identified. (NOTE: A specific withdrawal syndrome has not been identified for PCP, HALLUCINOGENS, OR 
INHALANTS). Withdrawal symptoms may occur following the cessation of prolonged moderate or heavy use of a psychoactive 
substance or a reduction in the amount used. 
 
SEDATIVES, HYPNOTICS, AND ANXIOLYTICS: 
Two (or more) of the following, developing within several hours to a few days after cessation of (or reduction in) sedative, hypnotic, 
or anxiolytic use, that has been prolonged: 
1. Autonomic hyperactivity (e.g., sweating or pulse rate greater than 100 bpm). 
2. Hand tremor. 
3. Insomnia. 
4. Nausea or vomiting. 
5. Transient visual, tactile, or auditory hallucinations or illusions. 
6. Psychomotor agitation. 
7. Anxiety. 
8. Grand mal seizures. 
 
CANNABIS: 
Three (or more) of the following signs and symptoms developing within approximately one week after cessation of cannabis use that 
has been heavy and prolonged (i.e., usually daily or almost daily use over a period of at least a few months): 
1. Irritability, anger, or aggression. 
2. Nervousness or anxiety. 
3. Sleep difficulty (e.g., insomnia, disturbing dreams). 
4. Decreased appetite or weight loss. 
5. Restlessness. 
6. Depressed mood. 
7. At least one of the following physical symptoms causing significant discomfort: abdominal pain, shakiness/tremors, sweating, 
fever, chills, or headache. 
 
STIMULANTS/COCAINE: 
Dysphoric mood AND two (or more) of the following physiological changes, developing within a few hours to several days after 
cessation of (or reduction in) prolonged amphetamine-type substance, cocaine, or other stimulant use: 
1. Fatigue. 
2. Vivid, unpleasant dreams. 
3. Insomnia or hypersomnia. 
4. Increased appetite. 
5. Psychomotor retardation or agitation. 
 
OPIOIDS: 
Three (or more) of the following, developing within minutes to several days after cessation of (or reduction in) opioid use that has 
been heavy and prolonged (i.e., several weeks or longer) or after administration of an opioid antagonist after a period of opioid use: 
1. Dysphoric mood. 
2. Nausea or vomiting. 
3. Muscle aches. 
4. Lacrimation or rhinorrhea (runny nose) 









Appendix C - MINI – Antisocial Personality Disorder 
 
 (” MEANS : GO TO THE DIAGNOSTIC BOX AND CIRCLE NO.) 
P1 Before you were 15 years old, did you: 
a. repeatedly skip school or run away from home overnight?   NO YES 
b. repeatedly lie, cheat, "con" others, or steal?     NO  YES 
c. start fights or bully, threaten, or intimidate others?    NO  YES 
d. deliberately destroy things or start fires?     NO YES 
e. deliberately hurt animals or people?      NO YES 
f. force someone to have sex with you?     NO YES 
 
ARE 2 OR MORE P1 ANSWERS CODED YES?    NO  YES 
 
DO NOT CODE YES TO THE BEHAVIORS BELOW IF THEY ARE EXCLUSIVELY 
POLITICALLY OR RELIGIOUSLY MOTIVATED. 
 
P2 Since you were 15 years old, have you: 
a. repeatedly behaved in a way that others would consider irresponsible, like failing to 
pay for things you owed, deliberately being impulsive or deliberately not working    to 
support yourself? 
 NO  YES 
b. done things that are illegal even if you didn't get caught (for example, destroying  
               property, shoplifting, stealing, selling drugs, or committing a felony)? 
 NO  YES 
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c. been in physical fights repeatedly (including physical fights with your spouse or 
children)?  
 NO  YES 
 
d. often lied or "conned" other people to get money or pleasure, or lied just for fun? 
 NO  YES 
e. exposed others to danger without caring? 
 NO  YES  
 
f. felt no guilt after hurting, mistreating, lying to, or stealing from others, or after 
damaging property? 
 NO  YES 
ARE 3 OR MORE P2 QUESTIONS CODED YES? 
 
















Appendix D - Childhood Trauma Questionnaire  
Instructions: These questions ask about some of your experiences growing up as a child and 
a teenager. For each question, circle the number that best describes how you feel. Although 
some of these questions are of a personal nature, please try to answer as honestly as you can. 








































1. I didn’t have enough to eat. 1 2 3 4 5 
2. I knew there was someone to take care of me and protect me 1 2 3 4 5 
3. People in my family called me things like “stupid”, ”lazy”, or “ugly”. 1 2 3 4 5 
4. My parents were too drunk or high to take care of me. 1 2 3 4 5 
5. There was someone in my family who helped me feel important or 
special. 
1 2 3 4 5 
6. I had to wear dirty clothes. 1 2 3 4 5 
7. I felt loved. 1 2 3 4 5 
8. I thought that my parents wished I had never been born. 1 2 3 4 5 
9. I got hit so hard by someone in my family that I had to see a doctor or go 
to the hospital. 
1 2 3 4 5 
10. There was nothing I wanted to change about my family. 1 2 3 4 5 
11. People in my family hit me so hard that it left bruises or marks. 1 2 3 4 5 
12. I was punished with a belt, a board, a cord, or some hard object. 1 2 3 4 5 
13. People in my family looked out for each other. 1 2 3 4 5 
14. People in my family said hurtful or insulting things to me. 1 2 3 4 5 
15. I believe that I was physically abused. 1 2 3 4 5 
16. I had the perfect childhood. 1 2 3 4 5 
17. I got hit or beaten so badly that it was noticed by someone like a 
teacher, neighbour, or doctor. 
1 2 3 4 5 
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18. I felt that someone in my family hated me. 1 2 3 4 5 
19. People in my family felt close to each other. 1 2 3 4 5 
20. Someone tried to touch me in a sexual way, or tried to make me touch 
them. 
1 2 3 4 5 
21. Someone threatened to hurt me or tell lies about me unless I did 
something sexual with them. 
1 2 3 4 5 
22. I had the best family in the world. 1 2 3 4 5 
23. Someone tried to make me do sexual things or make me watch sexual 
things. 
1 2 3 4 5 
24. Someone molested me. 1 2 3 4 5 
25. I believe that I was emotionally abused. 1 2 3 4 5 
26. There was someone to take me to the doctor if I needed it. 1 2 3 4 5 
27. I believe that I was sexually abused 1 2 3 4 5 

















Appendix E – Yale Brow Obsessive Compulsive Scale (adapted for drug use) 
Obsessive subscale – Questions 1 to 5 
1. How much of your time (when you’ve gone without using meth for 1 or 2 days) is 
occupied by ideas, thoughts, impulses or images related to meth/tik use? How frequently 
do these thoughts occur? 
   0 = None 
   1 = Mild (Less than 1 hour a day), or occasional intrusion (occur no more than 8 times     
a day) 
   2 = Moderate (1-3 hours a day), or frequent intrusion (occur more than 8 times a day, 
but most hours of the day are free of these thoughts) 
   3= Severe (4-8 hours a day), or very frequent intrusion (occur more than 8 times a day 
and occur during most hours of the day) 
   4 = Extreme (Greater than 8 hours a day), or near constant intrusion (too numerous 
to count and an hour rarely passes without several such thoughts occurring 
 
2. How much do the thoughts, impulses or images related to meth use interfere with your 
social or work (or role) functioning (1 to 2 days after the last time you used)? Is there 
anything you don’t do because of them? 
  0 = None 
   1 = Mild, slight interference with social or occupational activities, but overall 
performance not impaired 
  2 = Moderate, definite interference with social or occupational performance, but still 
manageable 
   3 = Severe, causes substantial impairment in social or occupational performance 




3. How much distress do these ideas, thoughts, impulses or images related to meth use cause 
you (when you’ve done without using meth for 1 to 2 days)? 
  0 = None  
  1 = Mild, infrequent and not too disturbing 
  2 = Moderate, frequent and disturbing, but still manageable  
  3 = Severe, very frequent and very disturbing 
  4 = Extreme, near constant, and disabling distress   
 
4. How much of an effort do you make to resist these thoughts (when you’ve gone without 
using meth for 1 to 2 days)? How often do you try to disregard or turn your attention away 
from these thoughts as they enter your mind (when you’ve done without using meth for 1 to 
2 days)? (Only rate effort made to resist, not success or failure in actually controlling these 
thoughts.)* 
   0 = Makes an effort to always resist, or symptoms are so minimal, doesn’t need to 
actively resist  
  1 = Tries to resist most of the time  
  2 = Makes some effort to resist 
  3 = Yields to all such thoughts without attempting to control them, but does so with some 
reluctance  
  4 = Completely and willingly yields to all such thoughts 
 
 
5. How much control do you have over these thoughts (when you’ve gone without using meth 
for 1 to 2 days)? How successful are you in stopping or diverting such thinking? 
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   0 = Complete control  
  1 = Much control, usually able to stop or divert such thoughts with some effort and 
concentration 
  2 = Moderate control, sometimes able to stop or divert such thoughts 
  3 = Little control, rarely successful in stopping such thoughts, can only divert such 
thoughts with difficulty 
  4 = No control, experienced as completely involuntary, rarely able to divert thinking even 
momentarily 
 
Compulsive Subscale – Questions 6 to 10 
6.  How much time per day do you spend using meth? (i.e. time spent getting and smoking 
tik [the clinician should take into account the amount of time as well as the frequency of 
the behavior per day]) 
   0 = None 
   1 = Mild (Spend less than 1 hour a day), or occasional use  
   2 = Moderate (1-3 hours a day), or frequent use 
   3= Severe (4-8 hours a day), or very frequent use 
   4 = Extreme (Greater than 8 hours a day), or near constant use 
 
7.  How much does your meth use interfere with your social or work (or role) functioning? 
Is there anything you don’t do because of your meth use? (If currently not working, 
determine how much performance would be affected if subject were employed.) 
      0 = None 
  1 = Mild, slight interference with social or occupational activities, but overall 
performance not impaired 
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     2 = Moderate, definite interference with social or occupational performance, but still 
 manageable 
  3 = Severe, causes substantial impairment in social or occupational performance 
  4 = Extreme, incapacitating 
 
8.  How would you feel if prevented from using meth when you wanted to use? How 
anxious or upset would you become? (Rate degree of distress subject would experience if 
meth use were suddenly interrupted without reassurance offered.) 
  0 = None 
   1 = Mild, only slightly anxious or irritated if meth use prevented 
  2 = Moderate, reports that anxiety or irritation would mount but remain manageable if 
meth use prevented 
  3 = Severe, prominent and very disturbing increase in anxiety or irritation if meth use 
interrupted 
  4 = Extreme, incapacitating anxiety or irritation from any intervention aimed at 
modifying meth use 
 
9.  How much of an effort do you make to resist using meth?  
(Only rate effort made to resist, not success or failure in actually controlling meth use.)* 
 0 = Makes an effort to always resist, or meth use is so minimal, doesn’t need to 
actively resist  
  1 = Tries to resist most of the time  
  2 = Makes some effort to resist 




  4 = Completely and willingly yields to all meth use 
 
10.  How strong is the drive to use meth? How much control do you have over the meth use? 
   0 = Complete control  
     1 = Much control, experiences pressure to use meth, but usually able to exercise 
voluntary control over it 
       2 = Moderate control, strong pressure to use meth, can control it only with difficulty 
       3 = Little control, very strong drive to use meth, must be carried to completion, can 
only delay with difficulty 
       4 = No control, drive to use meth experiences as completely involuntary and 
















Appendix F - Sheehan Disability Scale (SDS) 
Please circle the number that best describes the way you have felt over the past month 
 
1.) Work 
These symptoms have disrupted your work 
Not at all  Mildly  Moderately  Markedly Extremely 
 
0 1 2 3 4 5 6 7 8 9 10 
 
2.) Social Life 
These symptoms have disrupted your social life 
Not at all  Mildly  Moderately  Markedly Extremely 
 
0 1 2 3 4 5 6 7 8 9 10 
 
3.) Family life/Home responsibilities 
These symptoms have disrupted your family life/home responsibilities 
Not at all  Mildly  Moderately  Markedly Extremely 
 








Appendix G - SA MRC Unit’s Consent Form 
 
PARTICIPANT INFORMATION AND INFORMED CONSENT FORM  
(PATIENTS) 
TITLE OF RESEARCH PROJECT: Gambling disorder and methamphetamine use 
disorder: A neurocognitive, genetic and neuroimaging study 
REFERENCE NUMBERS:   SU HREC: N14/05/053   
      UCT HREC: 770/2014  
PRINCIPAL INVESTIGATORS:   SU: Prof Christine Lochner 
      UCT: Prof Dan Stein  
 
ADDRESS: MRC Unit on Risk and Resilience in Mental Disorders, Department of 
Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University 
 
CONTACT NUMBERS: Lochner: 021 – 938 9179; Stein: 021 – 404 2174 
We would like to invite you to participate in a research study that involves genetic analysis and 
possible long-term storage of blood or tissue specimens.  Please take some time to read the 
information presented here which will explain the details of this project.  Please ask the study 
staff any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied that you clearly understand what this research entails and 
how you could be involved.  Also, your participation is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect you negatively in any way whatsoever.  




This research study has been approved by the Health Research Ethics Committee at 
Stellenbosch University and the Human Research Ethics Committee at the University of 
Cape Town and it will be conducted according to international and locally accepted ethical 
guidelines for research, namely the Declaration of Helsinki, and the SA Department of Health’s 
2004 Guidelines: Ethics in Health Research: Principles, Structures and Processes. 
 
What is Genetic research? 
Genetic material, also called DNA, is usually obtained from a small blood sample.  
Occasionally genetic material is obtained from other sources such as saliva.  Genes are found 
in every cell in the human body.  Our genes determine what we look like and sometimes our 
susceptibility to certain kinds of diseases.  Worldwide, researchers in the field of genetics are 
continuously discovering new information.  This information may be of great benefit to both 
future generations and people today, who suffer from particular diseases or conditions. 
 
What does this particular research study involve? 
This study is part of a research project we are conducting to learn more about gambling disorder 
and methamphetamine use disorder.   
 
Doctors and scientists at the MRC Unit on Risk and Resilience in Mental Disorders, University 
of Stellenbosch, and the Department of Psychiatry, University of Cape Town, are collaborating 
with researchers from other research institutions worldwide to investigate the structure and 
functioning of selected brain areas in 40 individuals with gambling disorder and 40 individuals 
with methamphetamine use disorder.  This study also aims to identify the genes that may 
increase the risk for the development of these conditions.  Information from patients will be 
compared with 40 age- and gender-matched healthy controls. 
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This is not a treatment study.  Information is being collected for research purposes only. 
 
Why have you been invited to participate? 
You have been invited to participate because you have indicated (either to your doctor, or to 
the National Responsible Gambling Programme’s telephone counselling line which is affiliated 
with UCT’s Addiction division) that you excessively gamble or use methamphetamine (“tik”) 
to the extent that it affects your functioning.   
 
Gambling disorder (GD) or pathological gambling can be defined as the inability to resist the 
urge to gamble despite severely negative personal or social consequences.  Similarly, 
methamphetamine use disorder (MAUD) refers to the inability to resist taking the drug, and is 
often associated with repeated unsuccessful attempts to cut down, resulting in a failure to fulfill 
major obligations at work, school or home. 
 
What procedures will be involved in this research? 
If you decide to participate, we will ask you to attend 2-4 sessions, each with a different study 
focus.   
 
The first session will comprise an interview with a researcher and the drawing of bloods.  These 
procedures will last approximately 3-4 hours (with a break in-between, if need be). Depending 
on the preferences of your treatment centre, this session may be broken up into two sessions 
and the drawing of bloods and completion of questionnaires may be conducted in a group 
setting. The clinical interview will, amongst other things, include a number of questions related 
to gambling or methamphetamine use and your prior psychiatric history.  Approximately 20 
ml (4 teaspoons) of blood will be drawn from your arm.  We may need to contact you again to 
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get another blood sample should we fail to get a DNA sample (the genetic material) from your 
blood. The blood sample you give may be used to create a cell line. A cell line is living tissue 
that can be used to make more of your DNA at any time in the future.   Genetic material 
previously found to be associated with gambling disorder which may also play a role in brain 
activity, will also be investigated. This process will take place at the Division of Molecular 
Biology and Human Genetics, Faculty of Medicine and Health Sciences, at the University of 
Stellenbosch.  Should you not wish to provide us with a blood sample, you may provide us 
with a saliva sample instead.   
 
The second session will involve 2 hours of brain scanning followed by neuropsychological 
testing (i.e. computer based tasks to test abilities such as decision making) of approximately 
1.5 hours’ duration. This session may also be broken up into two sessions, depending on your 
or your treatment centre’s preference, as well as transport availability. MRI (brain scanning) 
makes use of magnetic fields and radio waves to examine internal structures of the body. The 
procedure is non-invasive and completely harmless. No 108onizing radiation (such as X-rays) 
or radio-active material are used during the study. MRI is particularly useful for imaging soft 
tissue such as the brain. It is capable of measuring certain characteristics of brain function. The 
procedure requires that you lie on your back with your head in a “tunnel” which is very similar 
to a CAT scan machine. The tunnel is open on both sides and is well lit and ventilated. You 
will at all times be in intercom contact with the radiographer, who will also be able to see you 
at all times. The examination will take about 90 minutes (with breaks if needed) and will be 
accompanied by a series of loud knocking sounds. There are no moving parts within the 
scanner, and the knocking sounds occur due to vibration of the machine in the magnetic fields. 
In some instances, the intravenous administration of contrast agent is also necessary, but you 
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will be notified in advance about this.  Finally, it is important that you do not move at any stage 
during the examination as this makes the images blurry.  
 
The initial screening and assessment of GD or MAUD patients as well as the drawing of bloods 
will take place either at the National Responsible Gambling Programme (NRGP) offices in 
Kenilworth, at the Faculty of Medicine and Health Sciences at the Tygerberg Campus of 
Stellenbosch University, or at the rehabilitation centre where you are currently being treated, 
depending on your preference for either location. The brain imaging will proceed at the recently 
established scanning centre at Groote Schuur Hospital (UCT). The computer-based tasks will 
proceed at the Faculty of Medicine and Health Sciences at the Tygerberg Campus of 
Stellenbosch University. You will receive grocery vouchers for participation and refreshments 
will be provided if requested. Where necessary, transport will also be provided. 
 
We may contact you later for further information, or request you to complete another interview 
at a later date, in order to obtain follow-up information that may be of use in our genetic 
analyses.  This may involve an assessment similar to the current assessment, including a series 
of interviews and/or another blood sample.  Your current participation is in no way binding to 
your future participation. 
 
Are there any risks involved in participation? 
There are no more than minimal medical or psychological risks associated with this study.  If 
you feel fatigued, uncomfortable, or in any way upset during any part of the session(s), you 
may ask to stop for a rest break or have the interview or scanning discontinued.  The research 
interview does not take the place of a full psychiatric evaluation.  You may experience some 
emotional discomfort when answering some questions.  If any particular question makes you 
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feel uncomfortable, you may discuss its importance with the specially trained interviewer.  You 
may choose not to answer any question should you feel uncomfortable. 
 
You may feel some pain associated with having blood drawn from a vein.  You may experience 
discomfort, bruising and/or other bleeding at the site where the needle is inserted.  
Occasionally, some people experience fleeting dizziness or feel faint when their blood is drawn.  
Some insurance companies may mistakenly assume that your participation in this study is an 
indication that you are at higher risk of a genetic disease, and this could hurt your access to 
health or other insurance.  We will not share any information about you, or your family, with 
an insurance company.  It is the opinion of the investigators that participation in this study does 
not constitute genetic testing.  Therefore, participation in this study should not be reported as 
genetic testing.   
 
You may feel some discomfort or fatigue associated with being in the brain scanner or while 
undergoing neuropsychological testing.   
 
Are there any benefits to your taking part in this study? Will the results of your 
participation be discussed with you? 
This study will hopefully provide useful data about the nature of problem gambling in South 
Africa, potentially filling gaps in the current body of knowledge regarding gambling.  
Individuals who might develop one of these conditions in the future, their family members, and 
future generations may benefit from the project if we can locate the genes and brain structures 
or functions that may have led to these symptoms.  That knowledge may then be used for 




Individuals who choose not to partake in this study are free to do so at no consequence and will 
be referred for treatment, if requested.  
 
How long will your blood/DNA sample be stored and where will it be stored? 
Samples will be safely stored at -80 degrees Celsius at the Division of Molecular Biology and 
Human Genetics, Faculty of Medicine and Health Sciences, at the University of Stellenbosch, 
and de-identified (identified by a code number), and access will be limited to authorised 
scientific investigators.  We also collaborate with researchers abroad; this means we may in 
future share DNA samples and anonymous (clinical or imaging) information with these sites 
to study your condition.   
 
Your DNA will be maintained permanently, unless you request to have it removed. If at any 
time in the future you wish to have your DNA or clinical data removed from the storage site, 
you may do so by contacting the researchers conducting this study. 
 
Will your clinical and genetics information be used for other research? 
You can choose to share your clinical and DNA information with other scientists through a 
central database. In other words, the data that have been collected may be used for future 
investigations. Other researchers would be able to learn from your data and would be able to 
conduct studies that include DNA from many countries.  This can lead to larger and better 
studies related to gambling disorder, methamphetamine use disorder and other health 
conditions.   
An “online database” is a database that is created from the central database.  Researchers all 
over the world have access to this database (this is called “data sharing”).  The DNA stored in 
this online database will be used for research into general medical conditions OR psychiatric 
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illnesses. If South African researchers wish to use your stored blood/DNA for additional 
research in this field, they will be required to apply for permission to do so from the Health 
Research Ethics Committee at Stellenbosch University and the Human Research Ethics 
Committee at the University of Cape Town.  If researchers from abroad wish to use your DNA 
information that has been stored on the online database, they will be required to apply for 
permission to do so from the National Institute of Health in the United States of America. If 
you wish to withdraw your data or your sample in the future, this is possible. However, please 
note that by the time we withdraw your data or your sample, it may already have been shared 
with other researchers. The United States National Institute for Mental Health (NIMH) 
Repository would, however, then instruct researchers to destroy your data and your sample if 
requested. 
 
Will your brain imaging data be shared with other researchers?  
In the same way as above, you can also choose to share your brain imaging data with 
researchers from other research institutions worldwide, to investigate, the structure and 
functioning of selected brain areas (anonymously). 
 
How will your confidentiality be protected? 
If you consent to participate in this study, your identity will be kept confidential.  Your answers 
will not be shared with other family members or anyone else except for staff members involved 
in this study.  All research information and laboratory samples obtained from you will be safely 
stored and identified by code number. This means that no identifying information will be 
shared. Access will be limited to authorised scientific investigators.  Any publications resulting 




Because some of your DNA/cells are going to be stored in the United States, there is a very 
small chance the United States government might forcibly gain access to it using one of their 
laws called “The Patriot Act”.  This Act is used when the United States government judges that 
access to DNA is important for security purposes. 
 
Will you or the researchers benefit financially from this research? 
You will not be paid to take part in this study although your travel expenses will be reimbursed. 
In addition to this, you will have the opportunity of winning some money in a monetary reward 
task. The exact amount you will receive is dependent on your performance on the task. 
 
Is there anything else that you should know or do? 
You can contact the principal investigator at Stellenbosch University, Christine Lochner, on 
021 – 938 9179 or CL2@sun.ac.za, or the principal investigator at the University of Cape 
Town, Dan Stein, on 021 – 404 2164 or dan.stein@uct.ac.za , if you have any further queries 
or encounter any problems. You can contact the UCT Faculty of Health Sciences Human 
Research Ethics Committee at 021 – 406 6346 if you have any concerns or complaints that 








Declaration by participant 
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By signing below, I …………………………………..…………. agree to take part in a 
genetic research study entitled Gambling disorder and methamphetamine use disorder: A 
neurocognitive, genetic and neuroimaging study. 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written in 
a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I have received a signed duplicate copy of this consent form for my records. 
 
Tick the options that apply: 
 I agree to take part in the study and consent to my blood being drawn. My 
anonymized information and blood sample will be stored and used for the current 
research project. Please destroy my DNA sample as soon as the current research 
project has been completed.   
 
 I agree that my anonymized information and blood or DNA sample can be stored, 
but I can choose to request at any time that my stored sample be destroyed.  I have 
the right to receive confirmation that my request has been carried out.   
 
I agree that my anonymized information and blood or DNA sample can be made 
available on an online database for use by other researchers, but I can choose to request 
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that my stored sample be destroyed. I have the right to receive confirmation that my 
request has been carried out. 
 
I agree that my anonymized brain imaging information can be made available for use 
by other researchers. 
 
Signed at (place) ...................................................... on (date) ............................................  
 
......................................................................   ..............................................................  
Signature of participant Signature of witness 
 
Declaration by investigator 
 
I (name) ………………………………………………… declare that: 
• I explained the information in this document to …………………..……………... 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research as 
discussed above. 
• I did/did not use an interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below). 
Signed at (place) ......................…........…………….. on (date) …………....……….. . 
......................................................................   ..............................................................  
Signature of investigator Signature of witness 




I (name) ………………………………………………… declare that: 
• I assisted the investigator (name) …………………………. To explain the 
information in this document to (name of participant) …………………………….. 
using the language medium of Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. . 
 
......................................................................   ..............................................................  
Signature of interpreter     Signature of witness  
 
 
 
 
 
 
 
 
 
